MXPA06010285A

MXPA06010285A - Tricyclic imidazopyridines

Info

Publication number: MXPA06010285A
Application number: MXPA/A/2006/010285A
Authority: MX
Inventors: Postius Stefan; Buhr Wilm; Jan Zimmermann Peter; Palmer Andreas; Brehm Christof; Simon Wolfgangalexander; Kromer Wolfgang; Vittoria Chiesa M
Original assignee: Altana Pharma Ag; Buhr Wilm; Palmer Andreas
Priority date: 2004-03-17
Filing date: 2006-09-08
Publication date: 2007-04-10

Abstract

The invention provides compounds of the formula (1), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid.

Description

DERIVATIVES OF 7H-8.9-DlHlDRO-PIRAN (2.3-C) IMIDAZO (1 .2A) PYRIDINE AND ITS USE AS INHIBITORS OF THE SECRETION OF GASTRIC ACID Field of the Invention The invention relates to novel compounds that are used in the pharmaceutical industry as active compounds for preparing drugs. Background of the Invention US Patent No. 4,468,400 discloses tricyclic imidazo [1,2- a] pyridines having different ring systems fused to the imidazopyridine skeleton, which compounds are reported to be suitable for treating peptic ulcer disorders. The International Applications of the Patent WO 95/27714, WO 98/42707, WO 98/54188. WO 00/17200, WO 00/2621 7, WO 00/50037, WO 00/6321 1, WO 01/72756, WO 01/72754, WO 01/72755, WO 01/72757, WO 02/34749, WO 03 / 014120, WO 03/01631 0, WO 03/014123, WO 03/068774 and WO 03/091253 describe tricyclic imidazopyridine derivatives having a very specific substitution pattern, of which compounds are reported in a similar manner, which are suitable to treat gastrointestinal disorders. J.J. Kaminski et al. , J. Med. Chem. 1985, 28 876-892, describe the cytoprotective properties of certain imidazopyridines. Description of the Invention The invention provides compounds of formula 1 wherein R 1 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl, C 1-4 alkoxy, C 1 -4-C1-4 alkoxy-alkyl, C1-4 alkoxycarbonyl, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or hydroxy-C1-4-alkyl, R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl, cyanomethyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4 -alkoxycarbonylamino, carboxyl, mono- or di-C 1-4 -alkylamino-C 1-4 -alkyl, C 1-4 4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1 -4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or where R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1 - 4- alkyl, C 1-4-alkoxy-C 1-4-alkoxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, fluoro-C 1-4 -alkoxy-C 1-4 -alkyl, cyano, the radical -CO -NR31R32, the radical - SO2NR31R32, the radical -CS-NR31R32, the radical -C = N (OH) -NR31R32 or the group Het wherein R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1- 4-alkyl, C 1-4-alkoxy, C 1-4-alkoxy-C 1-4 -alkyl, C 3-7-cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl or aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted by R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroxy-dazole, oxazole, imidazole, isoxazole, dihydroisoxa zol, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4- alkoxycarbonyl, carboxy-C1-4alkyl, C1-4alkoxycarbonyl-C1-4alkyl, halogen, hydroxyl, aryl, aryl-C1-4alkyl, aryloxy, aryl-C1-4alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4-alkyl, C 1-4-alkoxy, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, Arom is an aromatic radical substituted with R4, R5, R6 and R7 mono- or bicyclic, selected from the group consisting of phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furanyl (furyl) , benzofuranyl (benzofuryl), thiophenyl (thienyl), benzothiophenyl (benzothienyl), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl, wherein R4 is hydrogen, C1-4alkyl, hydroxy-C1-4alkyl, C1- 4-alkoxy, C 2-4-alkenyloxy, C 1-4 -alkylcarbonyl, carboxyl, C 1-4 -alkoxycarbonyl, carboxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl-C 1-4 -alkyl, halogen, hydroxyl , aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonyl In, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R5 is hydrogen, C1-4-alkyl, CI4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R6 is hydrogen , C 1-4 -alkyl or halogen and R 7 is hydrogen, C 1-4 -alkyl or halogen, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of d -4-alkyl , C1-4- alkoxy, carboxyl, C1-4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, with the proviso that, when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or cyanomethyl, so R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical -CS-NR31R32, the radical C = N (OH) -NR1R32 or the group Het wherein for the radical -CO-NR31R32 R31 is amino, hydroxyl, C1-4-alkoxy, C3- 7-cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4- alkyl or C3-7-cycloalkyl, and for the radicals -SO2-NR31R32, -CS-NR31R32, and C = N (OH) -NR31R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4 -I rent, C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl or aryl and R32 is hydrogen, C1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33 , R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroxydazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-al coxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl , nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4- alkyl, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, and you go out. C1-4-Alkyl means straight or branched chain alkyl radicals having 1 to 4 carbon atoms. Examples which may be mentioned are butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and methyl radicals. C3-7-Cycloalkyl means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, among which cyclopropyl, cyclobutyl and cyclopentyl are preferred. C3-7-Cycloalkyl-C 1-4 -alkyl means one of the aforementioned C 1-4 -alkyl radicals which is substituted with one of the aforementioned C 3-7 -cycloalkyl radicals. Examples that may be mentioned are the cyclopropylmethyl, cyclohexyl-methyl and cyclohexylethyl radicals. C1-4-Alkoxy means radicals which, in addition to the oxygen atoms, contain a straight or branched chain alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy radicals and preferably the ethoxy and methoxy radicals. C 1-4-Alkoxy-C 1-4-alkyl means one of the aforementioned C 1-4 -alkyl radicals which is substituted with one of the aforementioned C 1-4 -alkoxy radicals. Examples which may be mentioned are the methoxymethyl, methoxyethyl and butoxyethylene radicals. C1-4-Alkoxycarbonium (-CO-C1-4-alkoxy) means a carbonyl group to which one of the aforementioned C1-4-alkoxy radicals is attached. Examples which may be mentioned are the methoxycarbonyl radicals (CH3O-C (O) -) and ethoxycarbonyl (CH3CH2O-C (O) -). C2-4-Alkenyl means straight or branched chain alkenyl radicals having 2 to 4 carbon atoms. Examples that may be mentioned are the 2-butenyl, 3-butenyl, 1-propenyl and 2-propenyl (allyl) radicals. C2-4-Alkynyl means straight or branched chain alkynyl radicals having 2 to 4 carbon atoms. Examples that may be mentioned are the 2-butynyl radicals, 3-butynyl and, preferably, 2-propynyl radical (propargyl). Fluoro-C 1-4-alkyl means one of the aforementioned C 1-4 -alkyl radicals which is substituted with one or more fluorine atoms. An example that can be mentioned is the trifluoromethyl radical. "Hydroxy-C 1-4-alkyl" means the aforementioned C 1-4 -alkyl radicals which are substituted with a hydroxyl group. Examples that may be mentioned are the hydroxymethyl, 2-hydroxyethyl and 3-hydroxypropyl radicals. C3-4-Alkenyl means straight or branched chain alkenyl radicals having 3 to 4 carbon atoms. Examples that may be mentioned are the 2-butenyl, 3-butenyl, 1-propenyl and 2-propenyl (allyl) radicals. C3-4-Alkynyl means straight or branched chain alkynyl radicals having 3 to 4 carbon atoms. Examples which may be mentioned are the 2-butynyl, 3-butynyl and, preferably, 2-propynyl (propargyl) radicals. Hydroxy-C3-4-alkenyl means above-mentioned C3-4 alkenyl radicals which are substituted with a hydroxyl group. Examples that may be mentioned are 1-hydroxypropenyl or 1-hydroxy-2-butenyl radicals. Hydroxy-C3-4-alkynyl means above-mentioned C3-4 alkynyl radicals which are substituted with a hydroxy group. Examples which may be mentioned are 1-hydroxypropyl or 1-hydroxy-2-butynyl radicals. For the purposes of the invention, halogen is bromine, chlorine and fluorine. C1-4-Alkoxy-C1-4-alkoxy means one of the above-mentioned C1-4-alkoxy radicals which is substituted with an additional C1-4-alkoxy radical. Examples which may be mentioned are 2- (methoxy) ethoxy (CH3-O-CH2-CH2-O-) and 2- (ethoxy) ethoxy (CH3-CH2-O-CH2-CH2-O-) radicals. C 1-4-Alkoxy-C 1-4-alkoxy-C 1-4 -alkyl means one of the abovementioned C 1-4 -alkoxy-C 1-4 -alkyl radicals which is substituted with one of the abovementioned C 1-4 -alkoxy radicals . An example that can be mentioned is the 2- (methoxy) ethoxymethyl radical (CH3-O-CH2-CH2-O-CH2-). Fluoro-C 1-4-C 1-4 -alkoxy-alkyl means one of the aforementioned C 1-4 -alkyl radicals which is substituted with a fluoro-C 1-4 -alkoxy radical. Here, fluoro-C1-4-alkoxy means one of the above-mentioned C1-4-alkoxy radicals which is completely or predominantly substituted with fluorine. Examples of C1-4-alkoxy radicals completely or predominantly substituted with fluorine which may be mentioned are the 1, 1, 1, 3,3,3-hexafluoro-2-propoxy, 2-trifluoromethyl-2-propoxy radicals, 1, 1 , 1-trifluoro-2-propoxy, perfluoro-tert-butoxy, 2,2,3,3,4,4,4-heptafluoro-l-butoxy, 4,4,4-trifluoro-l-butoxy, 2, 2,3,3,3-pentafluoropropoxy, perfluoroethoxy, 1,2,2-trifluoroethoxy, in particular 1, 1, 2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, trifluoromethoxy and preferably the difluoromethoxy radical.

C1 -7-Alkyl means straight or branched chain alkyl radicals having 1 to 7 carbon atoms. Examples which may be mentioned are the heptyl radicals, heptyl- (5-methylhexyl), hexyl, isohexyl- (4-methylpentyl), neohexyl- (3,3-dimethylbutyl), pentyl, isopentyl (3-methylbutyl) ), neopentyl (2,2-dimethylpropyl), butyl, isobutyl, secbutyl, tert-butyl, propyl, isopropyl, ethyl and methyl. C1-4-Alkylcarbonyl means a radical which, in addition to the carbonyl group, contains one of the aforementioned C1-4-alkyl radicals. An example that can be mentioned is the radical aceti-lo. C2-4-Alkenylcarbonyl means a radical which, in addition to the carbonyl group, contains one of the aforementioned C2-4-alkenyl radicals. An example that may be mentioned is the ethe-nylcarbonyl radical or 2-propenylcarbonyl. C2-4-Alkynylcarbonyl means a radical which, in addition to the carbonyl group, contains one of the aforementioned C2-4-alkynyl radicals. An example that may be mentioned is the ethynylcarbonyl radical or 2-propynylcarbonyl. Carboxy-C1-4-alkyl means, for example, the carboxymethyl-(-CH2COOH) or carboxyethyl (-CH2CH2COOH) radical. C 1-4-Alkoxycarbonyl-C 1-4 -alkyl means one of the C 1-4 -alkyl radicals which is substituted with one of the aforementioned C 1-4 -alkoxycarbonyl radicals. An example that can be mentioned is the ethoxycarbonylmethyl radical (CH3CH2OC (O) CH2-). Di-C1-4-alkylamino means an amino radical which is substituted with two aforementioned identical or different C1-4-alkyl radicals. Examples that may be mentioned are the dimethylamino, diethylamino and diisopropylamino radicals. C1-4-Alkoxycarbonylamino means an amino radical which is substituted with one of the aforementioned C1-4-alkoxycarbonyl radicals. Examples which may be mentioned are the ethoxycarbonylamino and methoxycarbonylamino radicals. C1-4-Alkoxy-C1-4-alkoxycarbonyl means a carbonyl group to which one of the abovementioned C1-4-alkoxy-C1-4-alkoxy radicals is attached. Examples which may be mentioned are the 2- (methoxy) -ethoxycarbonyl radicals (CH3-O-CH2CH2-O-CO-) and 2- (ethoxy) ethoxycarbonyl (CH3CH2-O-CH2CH2-O-CO-). C 1-4-Alkoxy-C 1-4-alkoxycarbonylamino means an amino radical that is substituted with one of the above-mentioned C 1-4-alkoxy-C 1-4 alkoxycarbonyl radicals. Examples that may be mentioned are the 2- (methoxy) ethoxycarbonylamino and 2- (ethoxy) ethoxycarbonylamino radicals. C2-4-Alkenyloxy means a radical which, in addition to the oxygen atom, contains a C2-4-alkenyl radical. An example that may be mentioned is the allyloxy radical. Aryl-C 1-4-alkyl means a C 1-4 -alkyl radical substituted with aryl. An example that can be mentioned is the benzyl radical. Aryl-C 1-4-alkoxy means a C 1-4 -alkoxy radical substituted with aryl. An example that can be mentioned is the benzyloxy radical. The mono- or di-C 1-4-alkylamino radicals contain, in addition to the nitrogen atom, one or two of the aforementioned C 1-4 -alkyl radicals. Preference is given to the di-C1-4-alkylamino radical and in particular to the dimethyl-, diethyl- or diisopropylamino. Mono- or di-C 1-4-alkylamino-C 1-4 -alkyl means one of the aforementioned C 1-4 -alkyl radicals which is substituted with one of the mono- or di-C 1-4 -alkylamino radicals above mentioned. Preferred mono- or di-C 1-4-alkylamino-C 1-4 alkyl radicals are the mono- or di-C 1-4 alkylaminomethyl radicals. An example that can be mentioned is the radical dimethylaminomethyl (CH3) 2N-CH2. C 1-4-Alkylcarbonylamino means an amino group to which a C 1-4 -alkylcarbonyl radical is attached. Examples that may be mentioned are the propionylamino radicals (C3H7C (O) NH-) and acetylamino (acetamido, CH3C (O) NH-). Imidazolyl means an imidazole, dihydroimidazole or imidazo-lyridine radical, tetrazolyl means a tetrazolyl, dihydrotetrazolyl or tetrazolidinyl radical and oxazolyl means a 1,3-oxazole, dihydro-1,3-oxazole radical or a 1,3-oxazolidine radical. C 1-4-alkylsulfonyl means a sulfonyl radical to which one of the aforementioned C 1-4 -alkyl radicals is attached. Examples which may be mentioned are the methylsulfonyl radicals CH3-S (O2) -, ethylsulfonyl CH3CH2-S (O2) - and propylsulfonyl CH3CH2CH2-S (O2) -. Arsulfonyl means a sulfonyl radical to which one of the aforementioned aryl radicals is attached. Examples which may be mentioned are phenylsulfonyl radicals C6H5-S (O2) - or substituted phenylsulfonyl.

Aryl-C 1-4-alkylsulfonyl means a sulfonyl radical to which one of the aforementioned aryl-C 1-4 -alkyl radicals is attached. An example that can be mentioned is the benzylsulfonyl radical C6H5-CH2-S (O2) -. Mono- or di-C 1-4-alkylaminocarbonyl means a carbonyl radical to which a mono- or di-C 1-4 alkylamino radical is attached. Examples that may be mentioned are the dimethylaminocarbonyl, diethylaminocarbonyl and diisopropylaminocarbonyl radicals. The Arom radicals which can be mentioned are, for example, the following substituents: 4-acetoxyphenyl, 4-acetamidophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-benzyloxyphenyl, 4-benzyloxyfenyl, 3-benzyloxy -4-methoxyphenyl, 4-benzyloxy-3-methoxyphenyl, 3,5-bis (trifluoromethyl) phenyl, 4-butoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-chloro-6-fluorophenyl, 3-chloro -4-fluorophenyl, 2-chloro-5-nitrophenyl, 4-chloro-3-nitrophenyl, 3- (4-chlorophenoxy) phenyl, 2,4-dichlorophenyl, 3,4-diflurophenyl, 2,4-dihydroxyphenyl, 2, 6-dimethoxyphenyl, 3,4-dimethoxy-5-hydroxyphenyl, 2,5-dimethylphenyl, 3-ethoxy-4-hydroxyphenyl, 2-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 2-hydroxy-5-nitrophenyl, 3- methoxy-2-nitrophenyl, 3-nitrophenyl, 2,3,5-trichlorophenyl, 2,4,6-trihydroxyphenyl, 2,3,4-trimethoxyphenyl, 2-hydroxy-1-naphthyl, 2-methoxy-1-naphthyl , 4-methoxy-1-naphthyl, 1-methyl-2-pyrrolyl, 2-pyrrolyl, 3-methyl-2-pyrrolyl, 3,4-dimethyl-2-pyrrolyl, 4- (2-methoxycarbonyl-ethyl) -3- me til-2-pyrrolyl, 5-ethoxycarbonyl-2,4-dimethyl-3-pyrrolyl, 3,4-dibromo-5-methyl-2-pyrrolyl, 2,5-dimethyl-1-phenyl-3-pyrroyl, 5- carboxy-3-ethyl-4-methyl-2-pyrrolyl, 3,5-dimethyl-2-pyrrolyl, 2,5-dimethyl-1- (4-trifluoromethyl-enyl) -3-pyrrolyl, 1- (2, 6-dichloro-4-trifluoromethylphenyl) -2-pyrrolyl, 1- (2-nitrobenzyl) -2-pyrrolyl, 1- (2-fluorophenyl) -2-pyrrolyl, 1- (4-trifluoromethoxyphenyl) -2-pyrrolyl, - (2-Nitrobenzyl) -2-pyrrolyl, 1- (4-ethoxycarbonyl) -2,5-dimethyl-3-pyrrolyl, 5-chloro-1,3-dimethyl-4-pyrazolyl, 5-chloro-1-methyl -3-trifluoromethyl-4-pyrazolyl, 1- (4-chlorobenzyl) -5-pyrazolyl, 1,3-dimethyl-5- (4-chlorophenoxy) -4-pyrazolyl, 1-methyl-3-trifluoromethyl-5- ( 3- trif luoromethyl-enoxy) -4-pyrazolyl, 4-methoxycarbonyl-1- (2,6-dichlorophenyl) -5-pyrazolyl, 5-allyloxy-1-methyl-3-tpfluoromethyl-4-pyrazolyl, 5-chloro-1 phenyl-3-trifluoromethyl-4-pyrazolyl, 3,5-d-imethyl-1-phenyl-4-imidazole, 4-bromo-1-methyl-5-imidazolyl, 2-butylimidazolyl, 1-phenyl-1, 2 , 3-triazol-4-yl, 3-indolyl or, 4-indolyl, 7-indolyl, 5-methoxy-3-indolyl, 5-benzyloxy-3-indolyl, 1-benzyl-3-indolyl, 2- (4-chlorophenyl) -3-indolyl, 7-benzyloxy -3-indolyl, 6-benzyloxy-3-indolyl, 2-methyl-5-nitro-3-indolyl, 4,5,6,7-tetrafluoro-3-indolyl, 1- (3,5-difluorobenzyl) -3 -indolyl, 1-methyl-2- (4-trif luorofenoxi) -3-indolyl, 1-methyl-2-benzimidazolyl, 5-nitro-2-furyl, 5-hydroxymethyl-2-furyl, 2-furyl, 3 -furyl, 5- (2-nitro-4-trifluoromethylphenyl) -2-furyl, 4-ethoxycarbonyl-5-methyl-2-f-uryl, 5- (2-trifluoromethoxyphenyl) -2-furyl, 5- (4-methoxy) -2-nitrophenyl) -2-furyl, 4-bromo-2-furyl, 5-dimethylamino-2-furyl, 5-bromo-2-furyl, 5-sulfo-2-furyl, 2-benzofuryl, 2-thienyl, 3-thienyl, 3-methyl-2-thienyl, 4-bromo-2-thienyl, 5-bromo-2-thienyl, 5-nitro-2-thienyl, 5-methyl-2-thienyl, 5- (4-methoxyphenyl) ) -2-thienyl, 4-methyl-2-thienyl, 3-phenoxy-2-thienyl, 5-carboxy-2-thienyl, 2,5-dichloro-3-thienyl, 3-methoxy-2-thienyl, 2- benzothienyl, 3-methyl-2-benzothienyl, 2-bromo-5-chloro-3-benzothienyl, 2-thiazolyl, 2-amino-4-doro -5-thiazolyl, 2,4-dichloro-5-thiazolyl, 2-diethylamino-5-thiazolyl, 3-methyl-4-nitro-5-isoxazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 6-methyl -2-pyridyl, 3-hydroxy-5-hydroxymethyl-2-methyl-4-pyridyl, 2,6-dichloro-4-pyridyl, 3-chloro-5-trifluoromethyl-2 -pyridyl, 4,6-dimethyl-2-pyridyl, 4- (4-chlorophenyl) -3-pyridyl, 2-chloro-5-methoxycarbonyl-6-methyl-4-phenyl-3-pyridyl, 2-chloro-3 -pyridyl, 6- (3-trifluoromethyl-phenoxy) -3-pyridyl, 2- (4-chlorophenoxy) -3-pyridyl, 2,4-dimethoxy-5-pyrimidine, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 2-chloro-3-quinolinyl, 2-chloro-6-methoxy-3-quinolinyl, 8-hydroxy-2-quinolinyl and 4-isoquinolinyl. Suitable salts of the compounds of the formula 1 are - depending on the substitution - in particular all the acid addition salts. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids commonly used in pharmacy. Suitable ones are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, Benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, acid methanesulfonic acid or 3-hydroxy-2-naphthoic acid, where the acids are used in the preparation of the salt in an equimolar proportion or in a different proportion, depending on whether the acid is a mono- or polybasic acid and what is the desired salt. The pharmacologically unacceptable salts which can be obtained initially, for example, as products of the process in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically acceptable salts by processes known to the person skilled in the art. technique. It is known to the person skilled in the art that the compounds according to the invention and their salts can, for example when they are isolated in crystalline form, comprise varying amounts of solvents. The invention, accordingly, comprises all solvates and, in particular, all hydrates of the compounds of formula 1, and all solvates and, in particular, all hydrates of the salts of the compounds of formula 1. The compounds of formula 1 have at least one center of chirality in the backbone. The invention therefore provides all possible enantiomers in any mixing ratio, including the pure enantiomers, which are the preferred subject of the invention. One aspect of the invention (aspect a) relates to the compounds of formula 1, wherein R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl , C 1-4-alkoxycarbonyl, hydroxy-C 1-4 -alkyl, halogen, C 2-4 -alkenyl, C 2-4-alkynyl, f-C 1-4 -alkyl or cyanomethyl, R 1, R 3 and Arom have the meanings as indicated above, and the salts of these compounds. Another aspect of the invention (aspect b) relates to the compounds of formula 1, wherein R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, hydroxyl, C1-4-alkoxy, amino, mono - or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1 -4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO- NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R1, R3 and Arom have the meanings as indicated above, and the salts of these compounds. Another aspect of the invention (aspect c) relates to compounds of formula 1, wherein R3 is hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1 - 4-alkoxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, fluoro-C 1-4 -alkoxy-C 1-4 -alkyl or the radical -CO-NR 31 R 32, wherein R 31 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino or morpholino radical, R1, R2 and Arom have the meanings as indicated above, and the salts of these compounds. Another aspect of the invention (aspect d1) relates to the compounds of formula 1, wherein R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical -CS- NR31R32, the radical -C = N (OH) -NR1R32 or the group Het wherein for the radical -CO-NR31R32 R31 is amino, hydroxyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arisulfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, and the radicals -SO2-NR31R32, -CS-NR31R32, and C = N (OH) -NR1R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C1 -4-C 1-4 alkoxy-C 3-7-cycloalkyl, C 1-4 alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfonyl or aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C1-4-alkoxy-C1-4alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a residue c Clico, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholine, aziridino or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole , pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4- alkoxycarbonyl, carboxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl-C 1-4 -alkyl, halogen, hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonyl-amino or sulfonyl, R34 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, R1, R2 and Arom have the meanings indicated above, and the salts of these compounds. Another aspect of the invention (aspect d2) relates to compounds of formula 1, wherein R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31 R32, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C 1 -7-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached they form an aziridino or azetidino radical, R1, R2 and Arom have the meanings indicated above, and the salts of these compounds. Another aspect of the invention (aspect e) relates to compounds of formula 1, wherein R 2 has the meaning according to aspect a, R 3 has the meaning according to the aspect d 1 or d 2, R 1 and Arom have the meanings indicated above, and the salts of these compounds. Another aspect of the invention (aspect f) relates to compounds of formula 1, wherein R2 has the meaning according to aspect b, R3 has the meaning according to aspect c, R1 and Arom have the meanings indicated above , and the salts of these compounds. Another aspect of the invention (aspect g) relates to compounds of formula 1, wherein R2 has the meaning according to aspect b, R3 has the meaning according to aspect d1 or d2, R1 and Arom have the meanings indicated above, and the salts of these compounds. A particular aspect of the invention (aspect h) refers to compounds of formula 1, wherein Arom is phenyl R 1, R 2 and R 3 have the meanings indicated above. The invention also relates to compounds of the formula 1, wherein R1 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxy, C1- 4-alkoxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, C 2-4 -alkenoyl, C 2-4-alkynyl, fluoro-C 1-4 -alkyl or hydroxy-C 1-4 -alkyl, R 2 is hydrogen, C 1-4 4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4- alkynyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl, cyanomethyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4 -alkoxycarbonylamino, carboxyl, mono- or di-C 1-4 -alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3- 7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hyd roxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino radical, morpholino, aziridino or azetidino, R3 is hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alkyl, C1-4- alkoxycarbonyl, fluoro-C 1-4-alkoxy-C 1-4 -alkyl, an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO-NR 31 R 32, wherein R 31 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4- alkyl, C 1-4-alkoxy-C 1-4 -alkyl or C 3-7-cycloalkyl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is a mono- or bicyclic aromatic radical, substituted with R4, R5, R6 and R7 selected from the group consisting of phenyl, naphthyl, p Ridolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furanyl (furyl), benzofuranyl (benzofuryl), thiophenyl (thienyl), benzothiophenyl (benzothienyl), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolmyl, wherein R4 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, carboxyl- C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono - or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-akoxycarbonylamino, C 1-4-C 1-4 alkoxy-alkoxycarbonylamino or sulfonyl, R5 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R6 is hydrogen, C1-4-alkyl or halogen and R7 is hydrogen, C1-4-alkyl or halogen, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl , nitro, trifluoromethoxy, hydroxyl and cyano, with the proviso that when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy -C1-4-alkyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or cyanomethyl, then R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31R32, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy -C1-4- alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, and salts thereof. Compounds of formula 1 which must be mentioned are those, wherein R 1 is hydrogen, C 1-4 -alkyl, C 3-7-cycloalkyl R 2 is hydrogen, C 1-4 -alkyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl -C1- 4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, halogen, C2-4-alkenyl, C2-4-alkynyl , fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy -C1-4-alkoxycarbonyl, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO -NR21R22, wherein R21 is hydrogen, C1-7-a-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl , hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom to which they are attached form a adical pyrrolidino, piperidino, morpholino, aziridino or azetidino, R3 is hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alkyl , C 1-4-alkoxycarbonyl, fluoro-C 1-4-alkoxy-C 1-4 -alkyl, an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR 31 R 32, wherein R 31 is hydrogen, C 1-7 -alkyl, hydroxy -C 1 -4-alkyl, C 1-4-alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1 -4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is a phenyl substituted with R4, R5 , R6 and R7 wherein R4 is hydrogen or C1-4-alkyl, halogen, C1-4-alkoxy, trifluoromethyl R5 is hydrogen or C1-4-alkyl, halogen R6 is hydrogen and R7 is hydrogen with the proviso that when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-c Ilkalkyl-C1-4alkyl, C1-4alkoxycarbonyl, hydroxy-C1-4alkyl, halogen, C2-4alkenyl, C2-4alkynyl, fluoro-C1-4alkyl or cyanomethyl, then R3 is a imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO-NR31 R32, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1 -4- alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, and their salts. Particular mention may be made of those compounds of the formula 1 wherein R1 is hydrogen, C1-4-alkyl or C3-7-cycloalkyl, R2 is hydrogen, C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3 -4-alkynyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 alkylamino, C 1-4-alkylcarbonylamino, C 1-4-alkoxycarbonyl, C 1-4 -alkoxy-C 1-4-alkoxycarbonylamino, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl , C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7 -cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the aof nitrogen to which they are attached form a radical pyrrolidino, piperidino, morpholino, aziridino or azetidino, R3 is hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4 -alkoxy-C1-4alkyl, C1-4alkoxycarbonyl, fluoro-C1-4alkoxy-C1-4alkyl, an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31R32, wherein R31 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-C1-4alkoxy-C3-7alkyl or cycloalkyl, or wherein R31 and R32 together and including the nitrogen ato which they are attached form a pyrrolidic radical ino, piperidino, morpholino, aziridino or azetidino, Arom is a phenyl substituted with R4, R5, R6 and R7 wherein R4 is hydrogen or C1-4-alkyl, halogen, C1-4-alkoxy, trifluoromethyl R5 is hydrogen or C1- 4-alkyl, halogen R6 is hydrogen and R7 is hydrogen with the proviso that when R2 is hydrogen or C1-4-alkyl, then R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO-NR31R32, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together including the nitrogen ato which they are attached form an aziridino or azetidino radical, and their salts. Emphasis is placed on the compounds of formula 1, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4 -alkylcarbonylamino, C1-4-alkoxycarboni lamino, C1-4-alkoxy-C1-4 alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO- NR21R22, wherein R21 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO ~ NR31R32, wherein R31 is hydrogen, C1-4- alkyl or C3-7-cycloalkyl R32 is hydrogen, C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino radical or azetidino, Arom is phenyl and its salts. Emphasis is also placed on the compounds of formula 1, wherein R1 is C1-4-alkyl R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4- C 1-4 alkylamino-C 1-4 alkylcarbonyl, C 2-4 alkenylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 alkyl or C 1-4 alkoxy -C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is the radical -CO-NR31R32, wherein R31 is C1-4-alkyl and R32 is C1-4-alkyl Arom is phenyl and its salts. Emphasis is also placed on the compounds of formula 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31 R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen, C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino radical , aziridino or azetidino, Arom is phenyl, and its salts. Compounds of formula 1 which must also be mentioned are those, wherein R 1 is hydrogen, C 1 -4-alkyl, C 3-7-cycloalkyl R 2 is hydrogen, C 1-4 -alkyl, C 3-7-cycloalkyl, C 3-7 -cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, hydroxy-C 1-4 -alkyl, hydroxy-C 3-4 -alkenyl, hydroxy-C 3-4 -alkynyl, halogen, C 2-4 -alkenyl, C 2-4 -alkynyl, fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4-alkoxycarbonyl, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen , C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom a which are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy -C1-4-C1-4alkoxy-alkyl, C1-4alkoxycarbonyl, fluo-ro-C1-4-alkoxy-C1-4alkyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32 , the radical -CS-NR31R32, the radical C = N (OH) -NR1 R32 or the group Het wherein R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4 -alkoxy, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, hydroxy -C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33 , R34 and R35, selected from the group consisting of pyrrolidino, Piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted by R33, R34 and R35, selec-tioned from the group consisting of oxadiazol, dihydrooxazol, dihidroimi- dazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R 33 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 2-4 -alkenyloxy, C 1-4 -alkylcarbonyl, carboxyl, C 1-4 -alkoxycarbonyl , carboxy-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro , amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4-alkyl, C 1-4-alkoxy, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or feni the substituted having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, arom is a phenyl substituted with R4 and R5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl), where R4 is hydrogen or C1 -4-alkyl, halogen, C1 -4 alkoxy, trifluoromethyl R5 is hydrogen or C1 -4- alkyl, halogen with the proviso that when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl , halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or cyanomethyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31 R32, the radical -SO2-N R31 R32, the radical -CS-NR31 R32, the radical C = N (OH) -NR1 R32 or the group Het wherein for the radical -CO-NR31 R32 R31 is amino, hydroxyl, C1-4-alkoxy, C3 -7-cycloalkyl, C1-4-alkylsulfonyl, ariisu lfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, and for the radicals -SO2-NR31 R32, -CS-NR31 R32, and C = N (OH) -NR1 R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4- alkoxy, C1 -4 alkoxy-C1 -4-alkyl or C3-7-cycloalkyl, C1 -4-alkylsulfonyl, ariisulfonilo, aryl-C1 -4-alkylsulfonyl, aryl and R32 is hydrogen, C1 -7 alkyl, hydroxy- C 1-4 alkyl, C 1-4 alkoxy C 1-4 alkyl or C 3-7 cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R 33, R34 and R35, seleccio-swim from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino azetidino where in the case of pyrrolidino, piperidino, morpholino or at least one of R33, R34 substituents or, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selec-tioned from the group consisting of oxadiazol, dihydrooxazol, dihidroimi- dazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4 -alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, carboxy-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl , halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1- 4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alcoxicarboniIamino or sulfonyl, R34 is hydrogen, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C1- 4-alkyl, C1-4-alkoxy, carboxy lo, C1-4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts. Particular mention may be made of those compounds of formula 1, wherein R 1 is hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl, R 2 is hydrogen, C 1-4 alkyl, C 3-4 hydroxy alkenyl, hydroxy C3-4-alkynyl, hydroxy, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonyl, C1-4-alkoxy-C1-4 -alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy-C1-4 -alkyl, C1-4-alkoxy-C1-4alkyl-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical , R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-a C 1-4 -alkoxy-C 1-4 -alkoxycarbonyl, fluoro-C 1-4-C 1-4 -alkoxy-alkyl, cyano, the -CO-NR 31 R 32 radical, the -SO 2 -NR 31 R 32 radical, the -CS-radical -NR31R32, the radical C = N (OH) -NR1R32 or the group Het wherein R31 is hydrogen, amino, C1-7-a-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C1-4 -alkoxy-C1-4-alkyl, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl or aryl, and R32 is hydrogen, C1-7-alkyloxy, hydroxy-C1-4-alkyl , C 1-4-C 1-4 alkoxy-C 3-7 alkyl or cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R 33, R 34 and R 35, selected -nated from the group consisting of pyrrolidino, piperidino, piperazino, morpholine, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, in of R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, carboxy-C1 -4-alkyl, C 1-4-alkoxycarbonyl-C 1-4 -alkyl, halogen, hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonyl amine or sulfonyl, R34 is hydrogen, C1-4-alkyl, C1-4-alkoxy , C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or phenyl substituted having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, Arom is a phenyl substituted with R4 and R5, pyrr olyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl R 5 is hydrogen or C 1-4 -alkyl, halogen with the proviso that, when R2 is hydrogen or C1-4-alkyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31 R32, the radical -SO2-NR31 R32, the radical -CS-NR31 R32, the radical C = N (OH) -NR1 R32 or the group Het where for the radical -CO-NR31 R32 R31 is amino, hydroxyl, C 1-4 alkoxy, C 3-7 cycloalkyl, C 1-4 alkylsulfonyl, aryisulfonyl, aryl -C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, and for radicals - SO2-NR31 R32, -CS-NR31 R32, and C = N (OH) -NR1 R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C1 -4-alkoxy-C 1-4 -alkyl, C 3-7-cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl or aryl and R 32 is hydrogen, C 1-7-a l, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue , substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole. , wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, carboxy -C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4-alkyl , C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and its salts. Emphasis is also placed on the compounds of formula 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkenylene, hydroxy-C3-4-alkyl, hydroxyl, C1- 4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4 alkoxycarbonylamino, carboxyl, mono- or di- C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl and R 22 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy- C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is cyano, the radical -CO -NR31 R32, the radical -CS-NR31 R32, or the group Het wherein R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C 1-4 alkylsulfonyl, aryisulfonyl, aryl-C 1-4 alkylsulfonyl, aryl, and R 32 is hydrogen, C 1-7 -alkyl, or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, selected from the group it consists of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl , nitro, trifluoromethoxy, hydroxyl and cyano, Aro m is a phenyl substituted with R 4 and R 5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl R 5 is hydrogen or C 1-4- alkyl, halogen with the proviso that when R2 is C1-4-alkyl, then R3 is cyano, the radical -CO-NR31 R32, the radical -CS-NR31 R32, or the group Het where for the radical -CO -N R31 R32 R31 is C1 -4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, and for the radical -CS-NR31 R32 R31 is hydrogen, C1-7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl , or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted by R33, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, the substituent R33 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, soxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R 33 is hydrogen, C 1-4 -alkyl, C 1-4- alkoxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, halogen, hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three identical or different substituents from the group consisting of C 1-4 alkyl, C 1 - 4-alkoxy, carboxyl, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts. Emphasis is also placed on the compounds of formula 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1-4 -alkyl, C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, R3 is cyano, the radical -CO-NR31 R32, radical -CS-NR31 R32, or the group Het wherein R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl , aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group which consists of pyrrolidino, piperazino, aziridino or azetidino, and Het is a heterocyclic residue. ico, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, midazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl , C 1-4-alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4- alkoxycarbonyl, halogen, hydroxyl, Arom is a phenyl substituted with R 4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 alkoxy, trifluoromethyl with the condition that, when R2 is C1-4-alkyl, then R3 is cyano, the radical -CO-NR31 R32, the radical -CS-NR31 R32, or the group Het, wherein for -CO-NR31 R32 R31 is C1 -4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloal chyl, and for -CS-NR31 R32 R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino wherein in the case of pyrrolidino, the substituent R33 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkylcarbonyl, C1-4-alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, halogen, hydroxyl, and their salts. Emphasis is also placed on the compounds of formula 1, wherein R1 is C1-4-alkyl R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1- 4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is cyano, the radical -CO-NR31R32, the radical -CS-NR31R32, or the group Het wherein R31 is hydrogen, C1-7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1 -7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, selecci of the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, hydroxyl, Arom is a phenyl substituted with R4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl and its salts. Emphasis is also placed on the compounds of the formula 1, wherein R1 is CI -4-alkyl, R2 is C1-4-alkyl, R3 is cyano, the radical -C0-NR31 R32, the radical -CS-NR31 R32, or the Het group where for the radical -CO-NR31 R32 R31 C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1 -7-alkyl, or C3-7-cycloalkyl, for the radical -CS-NR31 R32 R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino where in the case of pyrrolidino, the substituent R33 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R3 3, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkylcarbonyl, C1-4- alkoxycarbonyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, hydroxyl, Arom is a phenyl substituted with R4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl, and their salts. Particular emphasis is also placed on the compounds of the formula 1, wherein R1 is C1-4-a] chyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1- 4- alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R22 is hydrogen or C1-4alkyl, R3 is cyano, an oxazolyl radical, the radical -CO-NR31R32, or the radical -CS-NR31R32, wherein R31 is C1-4-alkyl, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen or C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino, azetidino, hydroxyazetidino, or piperazine, wherein aryl is phenyl or phenyl substituted with C 1-4 alkoxy, Arom is phenyl, with the proviso that when R 2 is C 1-4 alkyl, then R 3 is cyano, an oxazolyl radical, the radical -CO-NR 31 R 32 , or the radical -CS-NR31R32, where for -CO-NR31R32 R 31 is C 3-7-cycloalkyl, C 1-4 alkylsulfonyl, aryl, C 1-4 alkoxy, R32 is hydrogen or C1-4-alkyl and for -CS-NR31R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino radical , azetidino, hydroxyazetidino, or piperazino, and their salts. Particular emphasis is also placed on the compounds of the formula 1, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino- C1-4- alkyl, C 1-4 alkylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R 22 is hydrogen or C 1-4 -R3 alkyl is the radical -CO-NR31R32, wherein R31 is C1-4-alkyl, R32 is C1-4-alkyl, Arom is phenyl, and salts thereof. Particular emphasis is also placed on the compounds of form 1, wherein R 1 is C 1-4 -alkyl, R 2 is C 1-4 -alkyl, R 3 is cyano, an oxazolyl radical, the -CO-NR 31 R 32 radical, or radical -CS-NR31R32, wherein for -CO-NR31R32 R31 is C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen, C1-4-alkyl and for -CS-NR31R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino radical, azetidino, hydroxyazetidino, or piperazino, wherein aryl is phenyl or phenyl substituted with C 1-4 alkoxy, Arom is phenyl, and its salts. Particular emphasis is also placed on the compounds of formula 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4- C 1-4 alkylamino-C 1-4 alkylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is an oxazolyl radical or the radical -CO-NR31 R32, wherein R31 is C1-4-alkyl or C3-7 -cycloalkyl R32 is hydrogen or C1-4alkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, Arom is phenyl, with the proviso that when R2 is C1 -4-alkyl, then R3 is an oxazolyl radical or the radical -CO-NR31 R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino radical or azetidin or, and its salts. Particular emphasis is also placed on the compounds of the formula 1, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino- C1-4- alkyl, C 1-4 alkylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R 22 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4alkyl, R 3 is the radical -CO-NR 31 R 32, wherein R 31 is C 1-4 -alkyl, R 32 is C 1-4 -alkyl, Arom is phenyl, and its salts. Particular emphasis is also placed on the compounds of the formula 1, wherein R1 is C1-4-alkyI, R2 is C1-4-alkyl, R3 is an oxazolyl radical or the radical -CO-NR31R32, wherein R31 is C3- 7-cycloalkyl R32 is hydrogen, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, Arom is phenyl, and its salts. Particular emphasis is also placed on the compounds of the form-mule 1, wherein R 1 is C 1-4-alkyl R 2 is carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl or the radical - CO-NR21R22, wherein R21 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is the radical -CO-NR31 R32, wherein R31 is C1-4-alkyl and R32 is C1-4-alkyl, Arom is phenyl, and salts thereof. Among the compounds of the formula 1 according to the invention, which include the compounds according to the a to h aspects, and those to be mentioned, particularly mentioned and in which emphasis and particular emphasis is placed, the compounds are optically preferred pure of the formula 1 -a.

Arom The invention also relates to the compounds of the formula 1a, wherein R 1 is hydrogen, C 1-4 -alkyl, C 3-7 -cycloalkyl, C 3-7-cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -4-C 1-4 alkoxy-C 1-4 alkyl-alkoxycarbonyl, C 2-4-alkenyl, C 2-4-alkynyl, fluoro-C 1-4 -alkyl or C 1-4 -hydroxy-alkyl, R 2 is hydrogen, C 1 -4 -4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4 -alkynyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl, cyanomethyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1- 4-alkylcarbonylamino, C 1-4 alkoxycarbonylamino, C 1-4 alkoxy-C 1-4 alkoxycarbonylamino, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2- 4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3 -7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, h idroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alky or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino, R3 is hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alkyl, C1-4- alkoxycarbonyl, fluoro-C 1-4-C 1-4 alkoxy-alkyl, an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR 31 R 32, wherein R 31 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4- alkyl, C 1-4-alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is an aromatic radical substituted with R4, R5, R6 and R7, mono- or bicyclic, selected from the group consisting of phenyl, naphthyl, pyrrole lyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, d-ololyl, benzimidazolyl, furanyl (furyl), benzofuranyl (benzofuryl), thiophenyl (thienyl), benzothiophenyl (benzothienyl), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl , wherein R4 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi -C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono - or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R5 is hydrogen, C1-4-alkyl, C1-4- alkoxy, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 6 is hydrogen, C 1-4 -alkyl or halogen and R 7 is hydrogen, C 1-4 -alkyl or halogen, wherein aryl is phenyl or substituted phenyl have one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, with the proviso that, when R 2 is hydrogen, C 1-4 -alkyl, C 3-7-cycloalkyl, C 3-7-cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, hydroxy-C 1-4 -alkyl, halogen, C 2-4 -alkenyl, C 2- 4-alkynyl, fluoro-C 1-4 -alkyl or cyanomethyl, then R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31 R32, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4 -alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, and their salts. Compounds of formula 1 to which they must be mentioned are those, wherein R 1 is hydrogen, C 1-4 -alkyl, C 3-7-cycloalkyl R 2 is hydrogen, C 1-4 -alkyl, C 3-7 -cycloalkyl, C 3-7- cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, hydroxy-C 1-4 -alkyl, hydroxy-C 3-4 -alkenyl, hydroxy-C 3-4-alkynyl, halogen, C 2-4 -alkenyl, C 2-4 -alkynyl, fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl , C 1-4 alkoxy, amino, mono- or di-C 1-4 alkylamino, C 1-4 alkylcarbonylamino, C 1-4 alkoxycarbonyl, C 1-4 alkoxy C 1-4 alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1- 7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, and R22 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1- 4-C 1-4 alkyloxy or C 3-7 cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R 3 is hydroxy- C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxycarbonyl, fluoro-C1-4-alkoxy- C1-4-alkyl, an im radical idazolyl, tetrazolyl or oxazolyl or the radical -CO- NR31R32, wherein R31 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is a phenyl substituted with R4, R5, R6 and R7 wherein R4 is hydrogen or C1-4-alkyl, halogen, C1-4- alkoxy, trifluoromethyl R5 is hydrogen or C1-4-alkyl, halogen R6 is hydrogen and R7 is hydrogen with the proviso that, when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl -C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or cyanomethyl, then R3 is a radical imidazolyl, tetrazolyl or oxazolyl or the radical -CO-NR31 R3 2, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, and their salts. Particular mention may be made of those compounds of formula 1 a, wherein R 1 is hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl, R 2 is hydrogen, C 1-4 alkyl, C 3-4 hydroxy alkenyl, hydroxy -C3-4- alkynyl, hydroxy, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-aicylcarbonyl, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1- 4- alkoxycarbonylamino, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO- NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino radical, morpholino, aziridino or azetidino, R3 is hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alky ilo, C 1-4 alkoxycarbonyl, C 1-4 fluoro-C 1-4 alkoxy-alkyl, a midazolyl, tetrazolyl or oxazolyl radical or the -CO-NR 31 R 32 radical, wherein R 31 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy- C 1-4 alkyl or C 3-7 cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is a phenyl substituted with R4, R5, R6 and R7 wherein R4 is hydrogen or C1-4-alkyl, halogen, C1-4-alkoxy, trifluoromethyl R5 is hydrogen or C4-4-alkyl, halogen R6 is hydrogen and R7 is hydrogen with the proviso that, when R2 is hydrogen or C1-4-alkyl, then R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO-NR31 R32, wherein R31 is C3-7-cycloalkyl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1- 4-alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, and their salts. Emphasis is placed on the compounds of the formula 1 a, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1 -4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO- NR21 R22, wherein R21 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl , C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3 -7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31 R32, wherein R31 is hydrogen, C1-4-alkyl or C3-7-cycloalkyl R32 is hyd R 4, R 4 and R 32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is phenyl and its salts . Emphasis is also placed on the compounds of formula 1 a, wherein R1 is C1-4-alkyl R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4 -alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1-4-alkyl or C1-4 -alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is the radical -CO-NR31 R32, wherein R31 is C1-4-alkyl and R32 is C1-4-alkyl. Arom is phenyl and its salts. Emphasis is also placed on the compounds of formula 1 a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR31 R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen, C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino radical, morpholino, aziridino or azetidinium, Arom is phenyl, and its salts. Compounds of the formula 1a which must also be mentioned are those, wherein R1 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7- C1-4-cycloalkyl-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, halogen, C2-4-alkenyl, C2-4- alkynyl, fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy -C1-4-alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22 , wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy -C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form n a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4 -alkoxy-C1-4-alkyl, C1-4-alkoxycarbonyl, fluo-ro-C1-4-alkoxy-C1-4-alkyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical - CS-NR31R32, the radical C = N (OH) -NR1R32 or the Het group in which R31 is hydrogen, amino, C1-7-alkyl, hydroxy, hydroxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, C1-4-alkylsulfonyl, arisulfonyl , aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or where R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted by R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a residue heterocyclic, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4-alkyl, hydroxy -C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1 -4-alkyl, halogen, hydroxyl, aryl , aryl-C 1-4 -alkyl, aryloxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C1-4-C 1-4 alkoxy-alkoxycarbonylamino or sulfonyl, R 34 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 4-alkyl, C 1-4-alkoxy, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4- alkoyl, C1-4- alkoxy, carboxyl, C1-4alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, Arom is a phenyl substituted with R4 and R5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) in where R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl R 5 is hydrogen or C 1-4 -alkyl, halogen with the proviso that, when R 2 is hydrogen, C 1-4 -alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1- 4-alkyl or cyanomethyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31 R32, the radical -SO2-N R31 R32, the radical -CS-NR31 R32, the radical C = N (OH) -NR1 R32 or the group Het wherein for the radical -CO-NR31 R32 R31 is amino, hydroxyl, C 1-4 -alkoxy, C 3-7-cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl , aryl and R32 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, and for the radicals -SO2-NR31 R32, - CS-NR31 R32, and C = N (OH) -NR1 R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxy-C1 -4-alkyl or C 3-7-cycloalkyl, C 1-4 alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -Alkoxy-C1-4- alkyl or C3-7-cic loalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected of the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, carboxy-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl- C 1-4 -alkyl, aryloxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkyl carbonylamino, C 1-4-alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4 -alkoxycarbonamino or sulfonyl, R34 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts. Particular mention may be made of those compounds of formula 1 a, wherein R 1 is hydrogen, C 1-4 -alkyl or C 3-7 -cycloalkyl, R 2 is hydrogen, C 1-4 -alkyl, C 3-4 -alkenyl, hydroxy -C3-4-alkynyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C 1-4-alkylcarbonylamino, C 1-4-alkoxycarbonyl, C 1-4-alkoxy-C 1-4-alkoxycarbonylamino, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1 -4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or where R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1 4-alkyl, C 1-4-C 1-4 alkoxy-C 1-4 alkoxy-alkyl, C 1-4-alkoxycarbonyl, fluoro-C 1-4-C 1-4 -alkoxy-alkyl, cyano, the radical CO-NR31R32, the radical-SO2-NR31R32, the radical -CS-NR31R32, the radical C = N (OH) -NR1R32 or the group Het wherein R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-4 -alkylsulfonyl, aryisulphonyl, aryl-C 1-4 -alkylsulfonyl or aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen to which they are joined form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroxydazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbom-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4 alkoxycarbonyl amine or sulfonyl , R34 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl , halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl , halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, Arom is a phenyl substituted with R4 and R5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R4 is hydrogen or C1-4alkyl, halogen, C1- 4-alkoxy, trifluoromethyl R5 is hydrogen or C1-4-alkyl, halogen with the proviso that, when R2 is hydrogen or C1-4-alkyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical -CS-NR31R32, the radical C = N (OH) -NR1R32 or the group Het wherein for the radical -CO-NR31R32 R31 is amino, hydroxyl, C 1-4 alkoxy, C 3-7 cycloalkyl, C 1-4 alkylsulfonyl, arylsulfonyl, aryl C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 alkyl, hydroxy C 1-4 alkyl, C 1-4-alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, and for the radicals -SO 2 -NR 31 R 32, -CS-NR 31 R 32, and C = N (OH) -NR 1 R 32 R 31 is hydrogen, amino, C 1-7 -alkyl, hydroxyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-4 -alkylsulfonyl, aryisulphonyl, aryl- C 1-4-alkylsulfonyl or aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, pipe razino, morpho-flax, aziridino or azetidino where in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted by R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroxy -dazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4alkyl, hydroxy-C1-4alkylamino, C1-4alkoxy, C2-4alkenyloxy, C1- 4-alkylcarbonyl, carboxyl, C 1-4-alkoxycarbonyl, carboxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl-C 1-4 -alkyl, halogen, hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl , R34 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl , halogen, trifluoromethyl or hid roxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, carboxyl, C 1-4 alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts. Emphasis is also placed on the compounds of the formula 1a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, hydroxyl, C1- 4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4 alkoxycarbonylamino, carboxyl, mono- or di-C1- 4-C 1-4 alkylamino-C 1-4 alkylcarbonyl, C 2-4-alkenylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 alkyl, hydroxy-C 1 -4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4 - alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is cyano, the radical -CO-NR31 R32 , the radical -CS-NR31 R32, or the group Het, wherein R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl or, C 1-4-alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the The nitrogen to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridi-no or azetidino, and Het is a heterocyclic residue, substituted with R33, selected from the group consists of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl , nitro, trifluoromethoxy, hydroxyl and cyano, Arom is a phenyl Used R4 and R5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl R 5 is hydrogen or C 1-4 -alkyl, halogen with the proviso that, when R 2 is C 1-4- alkyl, then R3 is cyano, the radical -C0-NR31 R32, the radical -CS-NR31 R32, or the group Het wherein for the radical -CO-NR31 R32 R31 is C1-4-alkoxy, C3-7-cycloalkyl , C 1-4-alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, or C 3-7 -cycloalkyl, and for the radical -CS-NR 31 R 32 R 31 is hydrogen, -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alky1, or C3 -7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino where in the case of pi rrolidino, piperidino, or morpholino, the substituent R33 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl, halogen, hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts. Emphasis is also placed on the compounds of formula 1 a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono - or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1- 4-alkyl, C 1-4-alkoxy-C 1-4 -alkyl and R 22 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl, R 3 is cyano, the radical -CO-NR 31 R 32 , the radical -CS-NR31 R32, or the group Het, wherein R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1- 4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected of the group consisting of pyrrolidino, piperazino, aziridino or azetidino, and Het is a heterocyclic residue. ico, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C 1-4-alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl , halogen, hydroxyl, Arom is a phenyl substituted with R 4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl with the proviso that , when R2 is C1-4-alkyl, then R3 is cyano, the radical -CO-NR31 R32, the radical -CS-NR31 R32, or the group Het wherein for -CO-NR31 R32 R31 is C1-4-alkoxy , C3-7-cycloalkyl, C 1-4 -alkylsulfonyl, arylsulfonyl, aryl-C 1-4 -alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, or C 3-7 -cycloalkyl lo, and for -CS-NR31 R32 R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyi, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino wherein in the case of pyrrolidino, the substituent R33 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three identical or different substituents of the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, hydroxyl, and their salts. Emphasis is also placed on the compounds of formula 1 a, wherein R1 is C1-4-alkyl R2 is hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4 -alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is cyano, the radical -CO-NR31 R32, the radical -CS-NR31 R32 , or the Het group in which R31 is hydrogen, C1-7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen , C1-7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkylcarbonyl, C1-4- alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, hydroxyl , Arom is a phenyl substituted with R4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 alkyl, halogen, C 1-4 alkoxy, trifluoromethyl and its salts. Emphasis is also placed on the compounds of the formula 1a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is cyano, the radical -CO-NR31R32, the radical -CS-NR31R32, or the Het group where for the radical -CO-NR31R32 R31 C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7 -alkyl, or C3-7-cycloalkyl, for the radical -CS-NR31R32 R31 is hydrogen, C1-7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1 -4-alkylsulfonyl, aryl and R32 is hydrogen, C 1 -7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33 , selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino where in the case of pyrrolidino, the substituent R33 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, selects of the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C14alkoxycarbonyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, hydroxyl, Arom is a phenyl substituted with R 4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl and their salts. Particular emphasis is also placed on the compounds of the formula 1 a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4 - alkylamino-C1-4-alkyio, C1-4-alkylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen or C1-4alkyl, R3 is cyano, an oxazolyl radical, the radical -CO-NR31R32, or the radical -CS-NR31R32, wherein R31 is C1-4-alkyl, C3-7-cycloalkyl, C1 -4-alkylsulfonyl, aryl, C 1-4 alkoxy, R 32 is hydrogen or C 1-4 alkyl-or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form an aziridino, azetidino, hydroxyazetidino, or piperazino radical , wherein aryl is phenyl or phenyl substituted with C 1-4 -alkoxy, Arom is phenyl, with the proviso that when R 2 is C 1-4 -alkyl, then R 3 is cyano, an oxazolyl radical, the radical -CO-NR 31 R 32 , or the radical -CS-NR31R32, where for -CO-NR 31R32 R31 is C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen or C1-4-alkyl and for -CS-NR31R32 R31 is C1-4-alkyl R32 is C1-4 -alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino, azetidino, hydroxyazetidino, or piperazino radical, and their salts. Particular emphasis is also placed on the compounds of the formula 1a, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino-C1-4- alkyl, C 1-4 alkylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R 22 is hydrogen or C 1-4 -R3 alkyl is the radical -CO-NR31R32, wherein R31 is C1-4-alkyl, R32 is C1-4-alkyl, Arom is phenyl, and salts thereof. Particular emphasis is also placed on the compounds of the form-mule 1a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is cyano, an oxazolyl radical, the -CO-NR31R32 radical, or the radical -CS-NR31R32, wherein for -CO-NR31R32 R31 is C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen, C1-4-alkyl and for -CS- NR31 R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino radical, azetidino, hydroxyazetidino, or piperazino, wherein aryl is phenyl or phenyl substituted with C 1-4 alkoxy, Arom is phenyl, and salts thereof. Particular emphasis is also placed on the compounds of formula 1 a, wherein R 1 is C 1-4 -alkyl, R 2 is C 1-4 -alkyl or C 1-4 -alkylcarbonyl, R 3 is the radical -CO-NR 31 R 32 or the radical -CS-NR31 R32, wherein R31 is C1-4-alkyl or C3-7-cycloalkyl, R32 is hydrogen or C1-4-alkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an azetidine radical, Arom is phenyl, with the proviso that when R2 is C1-4-alkyl, then R3 is the radical -CO-NR31 R32 or the radical -CS-NR31 R32, wherein for -CO-NR31 R32 R31 is C3-7-cycloalkyl, R32 is hydrogen, and for -CS-NR31 R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached; together they form an azetidine radical, and its salts. Particular emphasis is also placed on the compounds of formula 1 a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is the radical -CO-NR31 R32 or the radical -CS-NR31 R32, where for -CO-NR31 R32 R31 is C3-7-cycloalkyl, R32 is hydrogen, and for -CS-NR31 R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the Nitrogen atom to which they are attached form an azetidino radical, Arom is phenyl, and its salts. Particular emphasis is also placed on the compounds of form 1a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkylcarbonyl, R3 is the radical -CO-NR31R32, wherein R31 is C1-4- alkyl, R32 is C1-4-alkyl, Arom is phenyl, and salts thereof. Particular emphasis is also placed on the compounds of form 1a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1- 4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is an oxazolyl radical or the radical -CO-NR31R32, wherein R31 is C1-4-alkyl or C3- 7-cycloalkyl R32 is hydrogen or C1-4alkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, Arom is phenyl, with the proviso that when R2 is C1 -4-alkyl, then R3 is an oxazolyl radical or the radical -CO-NR31 R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino radical or azeti dino, and its salts. Particular emphasis is also placed on the compounds of the formula 1 a, wherein R 1 is C 1-4 -alkyl, R 2 is hydroxy-C 3-4-alkynyl, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C1-4-alkylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen , C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is the radical -CO-NR31 R32, wherein R31 is C1-4-alkyl, R32 is CI -4-alkyl, Arom is phenyl and its salts. Particular emphasis is also placed on the compounds of form 1a, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is an oxazolyl radical or the radical -CO-NR31R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, Arom is phenyl, and its salts. Particular emphasis is also placed on the compounds of formula 1a, wherein R1 is C1-4-alkyl R2 is carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl or radical -CO-NR21R22, wherein R21 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl , R3 is the radical -CO-NR31R32, wherein R31 is C1-4-alkyl and R32 is C1-4-alkyl Arom is phenyl and its salts. The compounds of formula 1 according to the invention can be synthesized from the corresponding starting compounds, for example according to reaction scheme 1 below. The synthesis is carried out in a manner known to the skilled person, for example as described in more detail in the examples following the reaction schemes. Reaction scheme 1: The compounds of the formula 2 can be converted directly into the compounds of the formula 1, for example by electrophilic aromatic substitution. Examples to be mentioned are the aminoalkylation or halogenation reactions for the synthesis of the compounds of the formula 1 with, for example, R 2 = mono- or di-C 1-4 alkylaminomethyl or halogen. Alternatively, the compounds of the formula 2 can be transformed first, for example by means of a Vilsmeier formylation, into compounds of the formula 3, followed by additional derivatization reactions, which are known to the expert (for example reduction of the carbonyl group, followed if desired by an etherification or oxidation of the formyl functionality to a carboxylic acid, followed if desired by reaction with a suitable amine and formation of an amide group R2 = -CO-NR21 R22, or addition of Grignard reagents, followed if is desired by an oxidation of the secondary hydroxyl group), which leads to the compounds of the formula 1. Another possible access to the compounds of the formula 1 is, for example, offered by the conversion of compounds of the formula 4a, for example by reaction of formation of CC bonds, as for example coupling reactions of Heck, Suzuki or Sonogashira, followed , if desired, by additional derivatization reactions known to the skilled person, such as, for example, reduction of unsaturated substituents R2 to the corresponding C1-4-alkyl chains. The compounds of the formula 4a can be prepared from the compounds of the formula 2 for example by means of a halogenation reaction, for example a bromination reaction using a bromination reagent, such as for example N-bromosuccinimide.

The compounds of the formula 1 can also be obtained by treating compounds of the formula 4b with an alkylating agent, e.g. , methyl iodide, and subsequent nucleophilic substitution of the quaternary ammonium group, for example. cyanide. The compounds of formula 4b can be prepared, for example, from compounds of formula 2 by electrophilic substitution with Eschenmo-ser salt. Yet another access to the compounds of formula 1 is, for example, offered by the conversion of compounds of formula 2 into compounds of formula 1 with R2 = NH2. This transformation can be achieved, for example, in analogy with the reactions described in J. Med. Chem., 1989, 32, 1686 or by nitration of the compounds of the formula 2 and subsequent reduction of the nitro group. Further transformations by means of reactions known to the person skilled in the art can then lead, if desired, to compounds of the formula 1 with R 2 = mono- or di-C 1-4-alkylamino, C 1-4-alkylcarbonylamino, C 1-4-alkoxycarbonylamino or C 1 - 4-alkoxy-C 1-4-alkoxycarbonylamino. Alternatively, the compounds of formula 1 with R 2 = NH 2 can be transformed into the corresponding diazonium salts. Then, additional compounds of formula 1 can be obtained, for example in which R.sub.2 is, for example, hydroxyl or C.sub.4-4-alkoxy, by substitution of the diazonium group by means of reactions known to the person skilled in the art. The compounds of formula 2 can be prepared, for example according to the reaction sequence outlined in Reaction Scheme 2.

Reaction scheme 2: The compounds of the formula 7 can be obtained, for example, from the compounds of the formula 5 by an O-alkylation followed by a thermally induced Claisen rearrangement reaction of the O-alkylation product of the formula 6. The protection of the alcohol functionality in the compounds of the formula 7 with a suitable Prot protection group, for example a pivaloyl group, using standard conditions leads to the compounds of the formula 8. which can be subjected in a subsequent reaction stage by way of example to a cross-metathesis reaction, for example using a suitable Grubbs catalyst, suitable for the introduction of the Arom residue. The reaction products of formula 9 can be deprotected and the ring closure can be carried out using methods known to the skilled person, for example under acidic conditions, which leads to the desired compounds of formula 2.

The compounds of the formula 5 can be prepared as shown in an exemplary manner in the reaction Scheme 3. Reaction Scheme 3: The preparation of the compounds of the formula 1 1 from the compounds of the formula 1 is carried out in a manner known per se to the person skilled in the art, for example in analogy to the reactions described in a manner example mode in the International Patent Application WO 03/014123. The hydrogenation of the compounds of the formula 1 1 in compounds of the formula 5 is carried out in a manner known per se to the person skilled in the art, using standard reaction conditions, such as for example hydrogen / Pd (0). Alternatively, the compounds of formula 1 can be prepared in a stereoselective manner by following the reaction steps as generally indicated in Reaction Scheme 4. Compounds of formula 1 3 can be prepared by asymmetric reduction of the compounds of the formula 12. Numerous methods are known to carry out the asymmetric reduction of prochiral ketones (see for example EN Jacobsen, A. Pfaltz, Y. Yamamoto, Comprehensive Asymmetric Catalysis, Vol. I-III, Springer, Berlin , 1 999) comprising inter alia catalytic hydrogenation, catalytic transfer hydrogenation, chiral reduction agents (eg, chiral boranes), achiral reduction agents in the presence of a chiral auxiliary or a chiral catalyst, hydrosilylation (achiral silane) in combination with a chiral catalyst), and enzymatic reduction. Catalytic asymmetric hydrogenation using Noyori chiral hydrogenation catalysts (RuCI2 [PP] [NN]) is the preferred method for the synthesis of enantiopure diols of formula 13. In the generic formula RuCI2 [PP] [NN], PP is used as a general abbreviation for a chiral diphosphine ligand and NN is used as an abbreviation for a chiral diamine ligand. A detailed description of the method and specific examples of hydrogenation catalysts can be found for example in Angew. Chem. 2001, 113, 40-75 and in the literature cited herein. The transformation of derivatives of formula 13 into 7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridines enantiopuras of formula 1 -a can be achieved by methods that come under SN2 conditions. For this purpose, the hydroxyl group in alpha position to the Arom radical can be transformed into a suitable LG leaving group, for example, by esterification with acid halides or sulfonyl chlorides. For the preparation of the compounds of the formula 14a, the phenolic hydroxyl group can be temporarily protected. Suitable protecting groups are described, for example, in T. W. Greene, P. G. Wuts "Protective Groups in Organic Synthesis" 3rd edition, J. Wiley & Sons, New York, 1999. Alternatively, the phenolic hydroxyl group in the compounds of formula 13 can be transformed into a suitable LG leaving group using for example the reagents mentioned above leading to the compounds of formula 14b. A related procedure is described in International Patent Application WO 95/27714. The enantiopure compounds of the formula 1-a can be obtained, for example, by heating solutions of these intermediates 14a or 14b in dipolar aprotic solvents, such as DMF or DMSO. The cyclization of the compounds of the formula 14b can be carried out, for example, in the presence of a base, such as, for example, sodium hydride. More conveniently, the cyclization of the diols of the formula 13 can be achieved under Mitsunobu conditions, for example using diisopropyl azodicarboxylate and triphenylphosphine.

Reaction scheme 4: The compounds of formula 1 2 are known, for example from WO 03/014123, or can be prepared in a known manner, analogously to known compounds. The purity of the compounds of formula 12 has a major impact on reaction conditions and the result of asymmetric catalytic hydrogenation to compounds of formula 13. In contrast to WO 03/014123, a purification step is required. additional, for example, a crystallization step in the presence of a suitable organic acid. A convenient method for transforming compounds of formula 12 into other compounds of formula 12 having a different R3 substituent is shown in Reaction Scheme 5 and can be illustrated by the following examples: 7- (3-aryl-3) esters -oxo-propyl) -8-hydroxy-imidazole [1,2-a] pyridine-6-carboxylates of the formula 15, wherein R33 is for example a C 1-4 -alkyl radical, can be converted into acetals of the formula 16, for example by reaction with 2,2-dimethoxypropane in the presence of acids. The breaking of the ester function, for example by saponification with sodium hydroxide, provides the corresponding carboxylic acids of the formula 1 7, which are then treated with a suitable coupling reagent, for example TBTU, followed by addition of the counterpart of the coupling, for example, an amine, providing derivatives of formula 18. Alternatively, the esters of formula 16 can be reduced to the corresponding primary alcohol, for example using lithium aluminum hydride, and the hydroxyl group can be activated by example by conversion to a halide or a sulfonate using for example thionyl chloride or methanesulfonyl chloride. The interconversion of the R3 substituent can then be carried out by nucleophilic displacement reactions using nucleophiles such as, for example, alkoxides. Finally, the ketones of formula 12 are obtained by breaking the acetals of formula 18. for example in the presence of acids such as hydrochloric acid. Reaction scheme 5: Another suitable method for the asymmetric synthesis of the compounds of the formula 1a is shown in Reaction Scheme 6. The compounds of the formula 1 9, which are obtained from the compounds of the formula 9 by known deprotection methods for the person skilled in the art, they can be transformed into chiral d of the formula 13, for example by double bond hydroboration. Chiral reagents, which are suitable for these transformations, are discussed, for example, in Aldrichimica Acta 1987, 20 (1), 9-24. An example that can be mentioned is isopinocamfeilborane. Alternatively, achiral hydroboration reagents can be used in combination with a chiral catalyst. The transformation of chiral d of formula 13 into compounds of formula 1-a was described above. Reaction scheme 6: Similarly, the optical antipodes of the formula 1 -b can be prepared in a stereoselective manner using the methods, which are described above and illustrated in the Schemes of the above reaction reactions. For this purpose, the transformations must be carried out using the corresponding enantiomer of the chiral catalyst / chiral reagent, respectively.

Another way of preparing the compounds of formula 1 is to reduce ketones of formula 12, using for example sodium borohydride, followed by cyclization of the d obtained, which can be carried out by acid catalysts or under Mitsunobu conditions (see for example WO 03/014123). The derivatization, if carried out, of the compounds of the formula 1 and of the compounds obtained according to the Scheme of reaction reactions 1 to 6 above (for example, conversion of one group R3 into another group R3 or conversion of a group R2 in another group R2) is carried out in a similar manner in a manner known to the skilled person. For example, if compounds where R2 and / or R3 = -CO-C1-4-alkoxy, or where R3 = -CO-NR31 R32 are desired, appropriate derivatization can be carried out in a manner known to the skilled person (e.g. metal-catalyzed carbonylation of the corresponding halo compound or conversion of an ester to an amide), for example in the step of an intermediate compound or more conveniently at a later point in time, for example conversion of a compound of formula 1 into another composed of formula 1. Specific examples of such transformations are shown in Reaction Scheme 7 and comprise for example condensation reactions between carboxylic acids of formula 20 and N-nucleophiles, which can be mediated for example by TBTU (O-benzotriazole-1 tetrafluoroborate). -il-N, N, N ', N'-tetramethyluronium) or CDI (N, N'-carbonyldiimidazole). Specific examples of N-nucleophiles are amines, sulfonamines, hydroxylamines, and hydrazines. The compounds of formula 21 are specific representatives of compounds of formula 1 and / or are valuable intermediates for the preparation of such derivatives. Examples of additional transformations of compounds of formula 21 are oxygen exchange vs. sulfur or the N-OH group, for example, using Lawesson's reagent or hydroxylamines, and elimination reactions, for example yielding compounds wherein R3 is a nitrile group or a heterocyclic residue, for example a dihydrooxazole residue or an oxadiazole residue . The nitriles of formula 22 can be converted into derivatives of formula 1, wherein R 3 is a heterocyclic group, for example, a dihydrooxazole, dihydroimidazole, or tetrazole group. The compounds of the formula 23, wherein the substituent R3 is a bromine atom, can also be considered as valuable intermediates for the synthesis of compounds of the formula 1 having different residues R3. A variety of different substituents are accessible, for example by palladium-catalyzed cross-coupling reactions using for example boronic acids, organotin derivatives, metal nitriles, alkenes, alkynes, and combinations of carbon monoxide with amines / alcohols. If desired, the compounds obtained from formula 1 can be further transformed by methods known to the person skilled in the art. Specific examples of suitable transformations are described in the examples that follow without being limited to them. Reaction scheme 7: The invention further relates to a process for the synthesis of a compound of formula 1, which comprises converting a compound of formula 2, wherein R 1, R 3 and Arom have the meanings as indicated above, in a compound of formula 1 wherein R1, R2, R3 and Arom have the meanings as indicated above. The invention further relates to a process for the synthesis of a compound of the formula 1-a comprising, - an asymmetric reduction of a compound of the formula 12 in a compound of the formula wherein R1, R2, R3 and Arom have the meanings indicated above - and conversion of a compound of formula 13 to a compound of formula 1-a or its salts. The invention further relates to a process for the synthesis of a compound of the formula 1-a, which comprises conversion of a compound of the formula 19 into a compound of the formula wherein R1, R2, R3 and Arom have the meanings as indicated above - and conversion of a compound of the formula 13 to a compound of the formula 1-a or its salts. The following examples serve to illustrate the invention in more detail without limiting it. Additional compounds of formula 1, the preparation of which is not explicitly described, can be prepared in a similar manner or in a manner known per se to the person skilled in the art, using customary processing techniques. The abbreviation ee means enantiomeric excess, TR means retention time, S / C means substrate to catalyst ratio, TLC means thin layer chromatography, v means volume. For the assignment of the NMR signals, the following abbreviations are used: s (singlet), d (duple-te), t (triplet), q (quartet), mc (multiplet centered), b (width). The following units are used: ml (milliliter), I (liter), nm (nanometer), mm (millimeter), mg (milligram), g (gram), mmol (millimole), N (normal), M (molar) , min (minute), MHz (megahertz). Additionally, the following abbreviations are used for the indicated chemical substances: DMSO dimethyl sulfoxide THF tetrahydrofuran DMF dimethylformamide DBU 1, 8-diazabicyclo [5.4.0] undec-7-ene TBTU tetrafluoroborate O-benzotriazole-1-yl-N, N, N ', N'-tetramethyluronium The optical purity of the compounds of formulas 1-a and 1-b was determined by capillary electrophoresis (CE) and / or high pressure liquid chromatography (HPLC). The experimental conditions for the separation of the enantiomers by HPLC are given for each example in the experimental section. The CE separation was carried out using one of the following experimental configurations: Instrument: Agilent CE-3D Capillarity: 64.5 cm x 75 μm, bubble cell (Agilent) Buffer: 50 mM sodium phosphate, pH 2.5 (Agilent) ) Chiral selector: heptaquis (2,3,6-tri-O-methyl) -β-cyclodextrin 40 mM (Ci-clolab) Voltage: 30 kV Temperature: 10 ° C. All HPLC columns used for preparative and analytical purposes are commercially available: CHIRALPAK® AD, CHIRALPAK® AD-H, CHIRALPAK® 50801: DAICEL Chemical Industries Ltd, Tokyo or Chiral Technologies-Europe SARL, llkirch, France If the points After the crystallization of the compound, the mixture of solvent / solvent that had been used for the purification is given in parentheses. If the chemical shifts of NMR (nuclear magnetic resonance) are provided without integration, superposition of the signal of the corresponding proton of the compound with signals of the solvent, water or impurities was observed.

I. Compounds of the formula 1-dimethylamide of 3-dimethylaminomethyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo- [1,2-a] pyridin-6 -carboxylic, iodide salt 2-Methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide was dissolved ( Example ix, 0.250 g, 0.75 mmol) in dry dichloromethane (10 ml) and N, N-dimethylmethyleneiminium iodide (0.138 g, 0.75 mmol) was added. The reaction mixture was stirred for 30 minutes at room temperature and then evaporated to dryness. A colorless solid was obtained which was dried under vacuum. Thus, 0.377 g of the title compound was obtained (97% yield). Melting point: 1 83-184 ° C 1 H NMR (dmso-d 6, 200 MHz): d = 2.14, 2.27 (2 mc, 2 H), 2.40 (s, 3 H), 2.55 (bs), 2.77, 2.90 (bs, s, 10 H ), 3.04 (s, 3 H), 4.64 (bs, 2 H), 5.31 (dd, 1 H), 7.43 (mc, 5 H), 8.29 (s, 1 H), 9.59 (bs, 1 H). 2. 6-dimethylcarbamoyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-3-carboxylic acid A solution of dimethylamide of 3-formyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1, 2-a] pyridine-6-carboxylic acid (example xi, 1 .10 g, 3.0 mmol) in THF (30 ml) and water (20 ml) was treated with sulfamic acid (0.50 g, 5.1 mmol) and cooled to 0 ° C. An aqueous solution (5 ml) of sodium chlorite (purity 80%, 0.47 g, 4.2 mmol) was added dropwise. The reaction mixture was stirred for 1 .25 hours at 0 ° C. After the addition of an aqueous solution (5 ml) of sodium sulfite (0.65 g, 5.2 mmol) the stirring was continued for 5 minutes. The reaction mixture was extracted with dichloromethane (2 x 50 ml). The organic phases were dried over sodium sulfate and concentrated under reduced pressure. The residue (750 mg) was dissolved in dichloromethane (10 ml) and water (10 ml). A pH value of 8 was adjusted by the addition of 2N sodium hydroxide solution (0.6 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 10 mL). The organic phases were discarded and the aqueous phase was acidified to pH 5 by the addition of 2N hydrochloric acid (1 ml). The aqueous phase was extracted with dichloromethane (2 x 20 ml), diluted with saturated sodium chloride solution (5 ml), and extracted again with another portion of dichloromethane. The combined dichloromethane phases were dried over sodium sulfate and concentrated under reduced pressure to yield the title compound (450 mg of a colorless solid, 39% yield). The aqueous phase was concentrated to a volume of 5 ml. After the addition of dichloromethane (10 ml) the pH value was readjusted to 5 by the addition of 2N hydrochloric acid (0.5 ml). Following the procedure described above, another 300 mg of the title compound was obtained (26% yield).

Melting point: 138 ° C 1 H NMR (CDCl 3, 200 MHz): d = 2.31 (mc, 2 H), 2.69, 2.74 (mc, s, 4 H), 2.91, 2.96 (mc, s, 4 H) , 3.16 (s, 3 H), 5.33 (dd, 1 H), 7.29 (mc), 7.43 (mc, 2 H), 8.93 (s, 1 H). 3. 2-Methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] midazo [1,2-a] pyridin-3,6-dicarboxylic acid bis-dimethylamide solution of 6-dimethylcarbamoyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-3-carboxylic acid (example 2, 0.120 g , 0.32 mmol) in dichloromethane (20 ml) was treated with TBTU (0.107 g, 0.33 mmol). The suspension was stirred for 1 hour at room temperature. A 2M solution of dimethylamine in THF (0.32 ml, 0.64 mmol) was added and stirring was continued for 1.5 hours at room temperature. The reaction mixture was quenched by the addition of water (20 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 10 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. A yellowish solid (0.124 g) was obtained and dried under vacuum. The title compound was isolated with 97% yield. Melting point: 1 90 ° C 1 H NMR (CDCl 3, 200 MHz): d = 2.26 (mc, 2 H), 2.47 (s, 3 H), 2.61 (mc, 1 H), 2.80 (mc), 2.95 ( s, 3 H), 3.10, 3.12 (2 s, 9 H), 5.33 (dd, 1 H), 7.39 (mc, 5 H), 8.06 (s, 1 H). 4. 3 - [(2-methoxyethyl) -amide] 6-dimethylamide of 2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1, 2-a] pyridine-3,6-dicarboxylic acid 6-Dimethylcarbamoyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] was dissolved. pyridine-3-carboxylic acid (example 2, 0.200 g, 0.53 mmol) in dichloromethane (30 ml) and treated with TBTU (0.177 g, 0.55 mmol). The suspension was stirred for 1 hour at room temperature. Methoxyethylamine (0.130 g, 1.73 mmol) was added and the reaction was continued for 1 hour at room temperature. The reaction was quenched by the addition of water (20 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 20 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The crude product (0.21 g) was purified by flash chromatography [6 g of silica gel, eluent: ethyl acetate / methanol = 95: 5 (v / v)]. A colorless solid (0.16 g, 70% yield) was isolated, which was the pure title compound. Melting point: 208 ° C 1 H NMR (CDCIs, 200 MHz): d = 2.27 (mc, 2 H), 2.61, 2.71 (mc, s, 4 H), 2.84, 2.96 (mc, s, 4 H) , 3.1 1 (s, 3 H), 3.42 (s, 3 H), 3.64 (mc, 4 H), 5.32 (dd, 1 H), 6.23 (bt, 1 H), 7.39 (mc, 5 H), 9.01 (s, 1 H). 5. 3- (1-Hydroxy-2-butynyl) -2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridin dimethylamide -6-carboxylic acid In a flame-dried flask filled with argon, 3-formyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] imidazole dimethylamide was suspended. [1,2-a] pyridine-6-carboxylic acid (example xi, 1.00 g, 2.8 mmol) in dry THF (50 ml). The suspension was cooled to -78 ° C and propynylmagnesium bromide (11.0 ml of a 0.5M solution in THF, 5.5 mmol) was added using a syringe. The reaction mixture was stirred for 1 hour at -78 ° C and for 2 hours at 0 ° C and was then quenched by the addition of water (30 ml) and dichloromethane (70 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 50 ml). The combined organic phases were washed with water (20 ml) and saturated sodium chloride solution (20 ml), dried over sodium sulfate, and concentrated under vacuum. A yellow foamy solid (1.07 g, 96% yield) was isolated which was characterized by 1 H-NMR spectroscopy as an almost pure diastereomer mixture of the title compound. 1 H-NMR (CDCl 3, 200 MHz): d = 1.84, 1.85 (2 s), 2.25 (mc, 2 H), 2.39 (s, 3 H), 2.60, 2.81 (2 mc, 2 H) , 2.93, 2.96 (2 s, S 3 H), 3.12 (s, 3 H), 3.74 (mc), 5.30 (mc, 1 H), 5.85 (mc, 1 H), 7.38 (mc, 5 H), 8.14, 8.15 (2 s, S 1 H). 6. 2-Methyl-3- (1-oxo-2-butynyl) -9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridin dimethylamide -6-carboxylic acid A solution of dimethylamide of 3- (1-hydroxy-2-butynyl) -2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1, 2-a] pyridine-6-carboxylic acid (example, 500 mg, 1.24 mmol) in dichloromethane (20 ml) was treated with manganese dioxide (4.0 g, 46 mmol). The suspension was stirred for 1 hour at room temperature and then filtered over Celite®. The concentration of the filtrate yielded a yellow foamy solid, which was purified by flash chromatography (silica gel, eluent: ethyl acetate). After evaporation of the corresponding fractions the title compound was isolated with 86% yield (430 mg of a yellow solid, almost pure according to 1 H-NMR spectroscopy).

Melting point: 21 6-217 ° C 1 H-NMR (CDC, 200 MHz): d = 2.16 (s, 3 H), 2.30 (mc, 2 H), 2.70 (mCf 1 H), 2.90, 2.91, 2.94 (s, mc, s, 7 H), 3.14 (s, 3 H), 3.48 (s), 5.34 (dd, 1 H), 7.39 (mc, 5 H), 9.28 (s, 1 H) . 7. 3- (1-Hydroxypropyl) -2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridin-6-dimethylamide -carboxylic In a flame-dried flask filled with argon, 3-formyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] imidazo [1], dimethylamide was suspended. 2-a] pyridine-6-carboxylic acid (example xi, 0.67 g, 1.8 mmol) in dry THF (50 ml). The suspension was cooled to -78 ° C and ethynylmagnesium bromide (7.4 ml of a 0.5M solution in THF, 3.7 mmol) was added using a syringe. The reaction mixture was stirred for 1 hour at -78 ° C and for 2 hours at 0 ° C and then quenched by the addition of water (40 ml) and dichloromethane (60 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 40 ml). The combined organic phases were washed with saturated sodium chloride solution (20 ml), dried over sodium sulfate, and concentrated under vacuum. The crude product was purified by flash chromatography [15 g of silica gel, eluent: dichloromethane / methanol = 100: 1 (v / v)]. A colorless foamy solid (0.63 g, 88% yield) was isolated which was characterized by 1 H-NMR spectroscopy as a pure diastereomer mixture of the title compound. 1 H NMR (CDCl 3, 200 MHz): d = 2.33 (mc, s, 5 H), 2.56, 2.58 (2 mc, 2 H), 2.79 (mc, 1 H), 2.93 (s, 3 H), 3.1 1 (s, 3 H), 5.30 (mc, 1 H), 5.86 (mc, 1 H), 7.38 (mc, 5 H), 8.1 1 (2 s, S 1 H). 8. 2-methyl-3- (1-oxopropinyl) -9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide A solution 3- (1-Hydroxypropyl) -2- methyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] imidazo [1,2-a] pyridin-6-dimethylamide carboxylic acid (example 7, 300 mg, 0.77 mmol) in dichloromethane (20 ml) was treated with manganese dioxide (2.4 g, 28 mmol). The suspension was stirred for 1 hour at room temperature and then filtered over Celite®. The concentration of the filtrate yielded a yellow foamy solid, which was purified by flash chromatography (silica gel, eluant: ethyl acetate). After evaporation of the corresponding fractions, the title compound was isolated in 67% yield (200 mg of a yellow solid). Melting point: 220-222 ° C 1 H-NMR (CDCl 3, 200 MHz): d = 2.29 (mc, 2 H), 2.71 (mc, 1 H), 2.92, 2.93, 2.94 (mc, 2 s, 7 H), 3.15 (s, 3 H), 3.48 (s, 1 H), 5.36 (dd, 1 H), 7.39 (mc, 5 H), 9.26 (s, 1 H). 9. 3-Acetyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo- [1,2-a] pyridine-6-carboxylic acid dimethylamide Dimethylamide was dissolved of 2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo- [1,2-a] pyridine-6-carboxylic acid (example ix, 1 .10 g, 3.3 mmol) in acetic anhydride (50 ml). After the addition of methanesulfonic acid (0.38 g, 3.9 mmol), the solution was heated for 1, 5 days at 140 ° C. The reaction mixture was concentrated and saturated sodium bicarbonate solution (90 ml) was added to adjust the pH to a value of 7-8. The aqueous phase was extracted with dichloromethane (2 x 70 ml, 1 x 30 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The brown residue was purified by flash chromatography (silica gel, eluent: ethyl acetate) yielding 0.57 g of the title compound (colorless solid, 46% yield). Melting point: 249-251 ° C 1 H-NMR (CDCl 3, 200 MHz): d = 2.29 (mc, 2 H), 2.61 -3.00, 2.61, 2.80, 2.94 (m, 3 s, 1 1 H), 3.14 (s, 3 H), 5.34 (dd, 1 H), 7.38 (mc, 5 H), 9.32 (s, 1 H). 10. (2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2- a] pyridin-6-yl) -aziridin-1-yl methanone A suspension of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii, 0.50 g, 1.5 mmol) in dichloromethane (25 ml) was treated with TBTU (0.50 g1.6 mmol). After a reaction time of 50 minutes at reflux, the yellow suspension was cooled to room temperature and aziridine (60 mg, 1.39 mmol) was added. The reaction mixture was stirred for 40 minutes at room temperature, at which time a clear solution was obtained. The reaction mixture was poured into saturated sodium bicarbonate solution, the phases were separated, and the aqueous phase was extracted with dichloromethane (2 x 20 ml). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The residue (0.75 g) was purified by flash chromatography [30 g of silica gel, eluent: dichloromethane / methanol = 100: 3 (v / v)]. A yellow oil was isolated and treated with a mixture of acetone (5 ml), diethyl ether (5 ml) and methanol (1 drop). The pure title compound was obtained in 15% yield (82 mg of a colorless solid). Melting point: 1 80-1 81 ° C (acetone / diethyl ether) 1 H-NMR (CDCl 3, 200 MHz): d = 2.23 (mc, 12 H), 3.08 (mc, 2 H), 5.29 (dd, 1 H), 7.39 (mc, 5 H), 8.31 (s, 1 H). eleven . (2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -]]] - [1,2-a] pyridin-6-yl) -azetidin- 1-l-methanone A suspension of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii, 1.70 g, 5.3 mmol) in dichloromethane (50 ml) was treated with TBTU (1.85 g, 5.8 mmol). After a reaction time of 1.5 hours at reflux, azetidine (316 mg, 373 μL, 5.53 mmol) was added. The resulting solution was stirred for 2 hours at room temperature. The reaction was quenched with water (50 ml), the phases were separated, and the aqueous phase was extracted with dichloromethane (2 x 20 ml). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The residue (3.46 g of a foamy solid) was purified by flash chromatography [100 g of silica gel, eluent: dichloromethane / methanol = 100: 3 (v / v)]. The corresponding fractions were evaporated and the solid obtained was dissolved in a mixture of dichloromethane (50 ml) and water (25 ml). Sodium hydroxide solution (2N) was added until a pH value of 1 was obtained. The phases were separated and the aqueous phase was extracted with dichloromethane (20 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. This yielded the pure title compound [1.68 g of a colorless solid, 88% yield]. Melting point: 254 ° C 1 H-NMR (CDCl 3, 200 MHz): d = 2.29, 2.37, 2.41 (mc, 2 s, 10 H), 276 (mc, 1 H), 2.99 (mc >); 1 H), 4.18 (bs, 4 H), 5.30 (dd, 1 H), 7.38 (mc, 6 H). 12. (3-hydroxy-azetidin-1 -iI) - (2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridin-6-yl) -methanone A suspension of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] -imidazo [1,2-a] pyridin acid -6-carboxylic acid (example xiii, 0.400 g, 1.24 mmol) in dichloromethane (20 ml) was treated with TBTU (0.470 g, 1.46 mmol). After a reaction time of 2 hours at reflux, 3-hydroxyazetidine (95 mg, 1.30 mmol) and DMF (4 ml) were added at room temperature. The reaction mixture was heated for 2 hours at 50 ° C. The suspension was cooled to 0 ° C and poured into a stirred mixture of sodium bicarbonate solution (20 ml) and dichloromethane (25 ml). Stirring was continued for several minutes, the phases were separated, and the aqueous phase was extracted with dichloromethane (3 x 10 mL). The combined organic phases were washed with water (2 x 10 ml), dried over sodium sulfate and concentrated under vacuum. The residue (1 g of a brown oil) was purified by flash chromatography [20 g of silica gel, eluent: dichloromethane / methanol = 1: 00: 3 (v / v)]. The corresponding fractions were evaporated and the solid obtained was washed with diethyl ether (3 ml). This yielded the pure title compound [170 mg of a colorless solid, 36% yield]. Melting Point: 306-308 ° C (diethyl ether) 1 H-NMR (DMSO-d6, 200 MHz): d = 2.1 0 (mc, 1 H), 2.26 (s, mc, 4 H), 2.37 (s) , 3 H), 2.66 (mc, 1 H), 2.92 (mc, 1 H), 3.85 (mc, 2 H), 4.23 (mc, 2 H), 4.50 (mc, 1 H), 5.26 (dd, 1 H), 5.75 (mc, 1 H), 7.42 (mc, 5 H), 7.85 (s, 1 H). 13. 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid cyclopropylamide A suspension of acid 2 , 3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii, 1.70 g, 5.3 mmol ) in dichloromethane (50 ml) was treated with TBTU (1.85 g, 5.8 mmol). After a reaction time of 1.5 hours at reflux, cyclopropylamine (314 mg, 381 μL, 5.50 mmol) was added. The resulting solution was stirred for 2 hours at room temperature. The reaction was quenched with water (50 ml), the phases were separated, and the aqueous phase was extracted with dichloromethane (2 x 20 ml). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The residue (3.2 g of a yellow foamy solid) was purified by flash chromatography [100 g of silica gel, eluent: dichloromethane / methanol = 100: 3 (v / v)]. The corresponding fractions were evaporated and the sticky solid obtained was suspended in a mixture of ethyl acetate (5 ml) and diethyl ether (40 ml). Stirring was continued for 1 hour at room temperature. The title compound was isolated by filtration and was dissolved in a mixture of dichloromethane (50 ml) and water (25 ml). A solution of sodium hydroxide (2N) was added until a pH value of 10 was obtained. The phases were separated and the aqueous phase was extracted with dichloromethane (20 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. This yielded the pure title compound [0.86 g of a colorless solid, 45% yield, the 1 H-NMR spectrum indicated the presence of methanol (7-8% by weight)]. Melting point: 260 ° C 1 H-NMR (DMSO-de, 200 MHz): d = 0.57 (mc, 2 H), 0.70 (mc, 2 H), 2.06 (mc, 1 H), 2.26 ( s, mc, 4 H), 2.37 (s, 3 H), 2.66-3.08 (m, 3 H), 3.17 (d, MeOH), 4.07 (q, MeOH), 5.23 (dd, 1 H), 7.42 ( mc, 5 H), 7.86 (s, 1 H), 8.42 (d, 1 H). 14. 2,3-dimethyl-9-phenyl-7H-8,9-dydrohydro [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid cyclobutylamide A suspension of 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii, 0.50 g, 1. 5 mmol) in dichloromethane (25 ml) was treated with TBTU (0.50 g, 1.6 mmol). After a reaction time of 1 hour at reflux, the suspension was cooled to room temperature and cyclobutylamine (10 mg) was added., 132 μl, 1.54 mmol). The reaction mixture was stirred for 1 hour at room temperature and then poured into saturated sodium bicarbonate solution (50 ml). The phases were separated, and the aqueous phase was extracted with dichloromethane (2 x 10 mL). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The residue (0.2 g) was purified by flash chromatography [40 g of silica gel, eluent: dichloromethane / methanol = 20: 1 (v / v)]. The corresponding fractions were evaporated and the solid obtained (300 mg) was suspended in a mixture of acetone (20 ml) and diethyl ether (20 ml). Stirring was continued for 30 minutes at 0 ° C and the pure title compound (270 mg, 47% yield) was isolated by filtration. Melting point: 257-258 ° C (acetone / diethyl ether) 1 H-NMR (CDCIs, 200 MHz): d = 1.79 (mc), 1.90-2.50, 2.33, 2.40 (m, 2 s, 12 H), 2.84 (mc, 1 H), 3.01 (mc, 1 H), 4.55 (mc, 1 H), 5.22 (dd, 1 H), 6.50 (d, 1 H), 7.39 (mc, 6 H) . 15. 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid phenylamide A suspension of acid 2 , 3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii, 0.400 g, 1.24 mmol) in dichloromethane (20 ml) was treated with TBTU (0.470 g, 1.46 mmol). After a reaction time of 2 hours at reflux, aniline (120 I, 123 mg, 1.32 mmol) was added at room temperature. The suspension was stirred for 1 hour at room temperature and diluted with DMF (6 ml). The reaction was continued for 1 hour at room temperature and for 30 minutes at 40 ° C. The brown suspension was cooled to 0 ° C and poured into a stirred mixture of sodium bicarbonate solution (20 ml) and dichloromethane (20 ml). Stirring was continued for several minutes, the phases were separated, and the aqueous phase was extracted with dichloromethane (3 x 8 ml). The combined organic phases were washed with water (2 x 10 ml), dried over sodium sulfate and concentrated under vacuum. The residue (900 mg of a yellow oil) was purified by flash chromatography [15 g of silica gel, eluent: dichloromethane / methanol = 100: 3 (v / v)]. The corresponding fractions were evaporated and the residue was dried under vacuum (390 mg of a yellow oil, 79% yield). The title compound was crystallized from acetone (1 ml), isolated by filtration, washed with cold acetone (1 ml) and diethyl ether (5 ml) and dried under vacuum. This yielded 190 mg of colorless crystals (39% yield). Melting point: 285-287 ° C (diethyl ether) 1 H-NMR (DMSO-d 6, 200 MHz): d = 2.09 (mc, 1 H), 2.29 (mc, s, 4 H), 2.41 (s, 3 H), 2.77 (mc, 1 H), 3.06 (mc, 1 H), 5.28 (dd, 1 H), 7.1 1 (t, 1 H), 7.42 (mc, 7 H), 7.73 (d, 2 H) ), 8.14 (s, 5H), 10.37 (s, 1 H). (2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] -imidazo [1, -a] pyridin-6-ethoxy-phenyl) -amide. -carboxylic acid A suspension of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid ( Example xiii, 1.00 g, 3.1 mmol) in dichloromethane (50 ml) was treated with TBTU (1.08 g, 3.4 mmol). After a reaction time of 1 hour at room temperature, p-phenetidine (286 mg, 271 μL, 2.08 mmol) was added. The resulting solution was stirred for 2 hours at room temperature. More p-phenetidine (143 mg, 135 μl, 1.04 mmol) was added and stirring was continued for 1 hour at room temperature. The reaction was quenched with sodium bicarbonate solution, the phases were separated, and the aqueous phase was extracted with dichloromethane (2 x). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The residue (1.85 g) was crystallized from acetone / ethyl acetate / diethyl ether [2: 10: 10 (v / v / v)]. The resulting suspension was stirred for 1 hour at room temperature and the precipitate was isolated by filtration (880 mg). With the concentration of mother liquor more precipitate formed, which was also isolated by filtration (1 93 mg). The two batches were combined and purified by flash chromatography [silica gel, eluent: dichloromethane / methanol = 1: 00: 3 (v / v)]. The corresponding fractions were evaporated and the foamed solid obtained was washed with diethyl ether. This yielded the pure title compound (670 mg, 49% yield). Melting point: 223 ° C (diethyl ether) 1 H-NMR (CHCl 3, 200 MHz): d = 1.42 (t, 3 H), 2.1 1 (mc, 1 H), 2.27, 2.33, 2.39 (s) , mc, s, 7 H), 2.89 (mc, 1 H), 3.10 (mc, 1 H), 4.04 (q, 2 H), 5.14 (dd, 1 H), 6.87 (d, 2 H) , 7.25 (mc), 7.38 (mc, 2 H), 7.44 (s, 1 H), 7.64 (d, 2 H), 8.71 (bs, 1 H). 17. N- (2,3-d-rhenyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridin-6-carbonyl) - metans ulf onamide A suspension of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii) , 0.80 g, 2.5 mmol) in dry THF (30 ml) was treated with N. N'-carbonyldiimidazole (0.80 g, 4.9 mmol). After a reaction time of 2 hours at 40 ° C, a brown solution was obtained. DBU (0.75 g, 4.9 mmol) and methanesulfonamide (0.47 g, 4.9 mmol) were added and stirring was continued for 1 hour at room temperature. The reaction mixture was poured into water (30 ml) and dichloromethane (50 ml), the phases were separated, and the aqueous phase was extracted with dichloromethane (30 ml). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The residue (1.5 g of a brown foamy solid) was purified by flash chromatography [45 g of silica gel, eluent: dichloromethane / methanol = 1: 00: 3 (v / v)]. The corresponding fractions were evaporated and the title compound was isolated (0.70 g, 71% yield). Melting point: 210 ° C 1 H-NMR (dmso-d 6, 200 MHz): d = 2.09 (mc, 1 H), 2.30 (s, mc, 4 H), 2.41 (s, 3 H), 3.00, 3.1 0 (s, mc, 5 H), 5.28 (dd, 1 H), 7.44 (mc, 5 H), 8.14 (s, 1 H). 18. (2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -. Imidazo [1,2-a] pyridin-6-yl) -piperazin-1 - il-methanone A suspension of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii) , 0.90 g, 2.8 mmol) in dry THF (30 ml) was treated with N, N'-carbonyldiimidazole (0.91 g, 5.6 mmol). After a reaction time of 2 hours at 40 ° C, a brown solution was obtained. DBU (0.85 g, 5.6 mmol) and pipe-razine (0.48 g, 5.6 mmol) were added and the stirring was continued for 2.5 days at room temperature. The reaction mixture was poured into water (30 ml) and dichloromethane (50 ml), the phases were separated, and the aqueous phase was extracted with dichloromethane (30 ml). The combined organic phases were washed with water (20 ml), dried over sodium sulfate, and concentrated under vacuum. The residue (1.3 g) was purified by flash chromatography [40 g of silica gel, eluent: dichloromethane-methanol = 1: 5: (v / v)]. Evaporation of the corresponding fractions gave a yellow sticky solid, which was washed with diethyl ether (30 ml). The precipitate was isolated by filtration, washed with diethyl ether (5 ml) and dried under vacuum. The title compound (0.24 g) was further purified by flash chromatography [10 g of silica gel, eluent: ethyl acetate / methanol = 9: 1 (v / v)] and obtained in 13% yield ( 0.14 g of a foamy solid). 1 H-NMR (DMSO-d6, 200 MHz): d = 2.16, 2.25, 2.35 (mc, 2 s, 8 H), 2.73 (bs, superposition with the dmso signal), 3.20 (bs, superposition with the signal of water), 3.58 (bs, 2 H), 5.27 (dd, 1 H), 7.43 (mc, 6 H), 7.76 (s, 1 H). 19. 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid methoxy-methyl acid 2,3-dimethyl-9-phenyl-7H-8,9-dhydro-pyran [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid suspension (example xiü, 0.400 g, 1.24 mmol) and TBTU (0.470 g, 1.46 mmol) in dichloromethane (20 ml) was heated to reflux for a period of 2 hours. N, O-dimethylhydroxylamine hydrochloride (150 mg, 1.54 mmol) was treated with saturated sodium bicarbonate solution (3 ml) and diethyl ether (3 ml) and the phases were separated. At room temperature, the ether phase (containing N, O-dimethylhydroxylamine) was added to the reaction mixture. The suspension was stirred for 2 hours at room temperature. The same amount of N, O-dimethylhydroxylamine was added and the reaction mixture was heated for 2 hours at 50 ° C. Another equivalent of the reagent was added and the reaction continued for 2 hours at 50 ° C. The brown suspension was cooled to 0 ° C and poured into a stirred mixture of sodium bicarbonate solution (20 ml) and dichloromethane (25 ml). Stirring was continued for several minutes, the phases were separated, and the aqueous phase was extracted with dichloromethane (3 x 8 ml). The combined organic phases were washed with water (2 x 10 mL), dried over sodium sulfate and concentrated under vacuum. The residue (380 mg of a brown oil) was purified by flash chromatography [15 g of silica gel, eluent: dichloromethane / methanol = 1: 00: 3 (v / v)]. The corresponding fractions were evaporated and the residue (200 mg) was crystallized from acetone (0.5 ml) and diethyl ether (4 ml). The title compound was isolated by filtration, washed with a few drops of cold acetone and diethyl ether (3 ml), and dried under vacuum. This afforded 150 mg of a colorless solid (33% yield). Melting point: 1 90-1 92 ° C (acetone / diethyl ether) 1 H-NMR (DMSO-d 6, 200 MHz): d = 2.12 (mc, 1 H), 2.26 (mc, s, 4 H), 2.36 (s, 3H), 2.54 (mc), 2.81 (mc, 1 H), 3.26 (s, 3 H), 3.57 (s, 3 H), 5.26 (dd, 1 H), 7.42 (mc, 5 H) ), 7.92 (s, 1 H). 20. 6- (4,5-Dihydro-oxazol-2-yl) -2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2] -a] pyridine Three samples of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] imidazo [2-chloroethyl] -amide [1, 2-a] pyridine-6-carboxylic acid (example xv, 3 x 70 mg, 0.55 mmol) were transferred into microwave tubes and dissolved in dry DMF (3 x 3 ml). The yellow solution was heated at 150 ° C for 20 minutes and at 170 ° C for another 20 minutes. The reaction mixtures were combined and evaporated to dryness. The residue was purified by flash chromatography [22 g of silica gel, eluent: ethyl acetate / methanol = 100: 3 (v / v)]. Evaporation of the corresponding fractions gave a red solid (106 mg, mixture of the title compound with unprocessed starting material as indicated by TLC analysis), which was further purified by preparative HPLC. The title compound was isolated in 14% yield (27 mg of a colorless solid). 1 H NMR (CDCl 3, 200 MHz): d = 2.30, 2.40, 2.41 (mCf 2 s, 8 H), 3.15 (mc, 2 H), 4.09 (mc, 2 H), 4.38 (mc, 2 H) , 5.30 (dd, 1 H), 7.39 (mc, 5 H), 8.09 (s, 1 H). twenty-one . 6-cyano-2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine A suspension of 2,3-amide dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid (example xvi, 200 mg, 0.62 mmol) in dry acetonitrile (10 ml) was treated with sodium azide (590 mg, 9.08 mmol) and tetrachlorosilane (0.35 ml, 0.52 g, 3.0 mmol). The white suspension was heated at 95 ° C for 3 days. The reaction mixture was cooled and poured into saturated sodium bicarbonate solution (3 ml), water (15 ml), and dichloromethane (20 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 5 ml). The combined organic phases were washed with water (5 ml), dried over sodium sulfate, and evaporated to dryness. The yellow-brown residue (130 mg) was purified by flash chromatography (10 g of silica gel, eluent: dichloromethane / methanol = 20: 1 (v / v).] The corresponding fractions were evaporated and the residue was dried under vacuum This afforded the pure title compound (90 mg of a slightly brown solid, 49% yield) Melting point: 266-268 ° C 1 H-NMR (CDCl 3, 200 MHz): d = 2.18 (mc, 1 H ), 2.27 (mc, s, 4 H), 2.39 (s, 3 H), 2.74 (nric, 1 H), 3.00 (mc, 1 H), 5.27 (dd, 1 H), 7.42 (mc, 5 H) ), 8.65 (s, 1 H). II. Compounds of the formula 1-α (dimethylamide) of (9S) -3-acetyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1, 2] -a] pyridine-6-carboxylic acid The resolution of 3-acetyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1], dimethylamide was determined. Racemic 2-a] pyridine-6-carboxylic acid (example 9, 202 mg, 0.54 mmol) by preparative chromatography using a CH IRALPAK® AD-H 5 μm 250 x 20 mm column. The mobile phase consisted of a mixture of n-heptane and ethanol [85: 1 5 (v / v)]. The separation was carried out at room temperature with a flow rate of 20 ml / min. The products were detected at a wavelength of 300 nm. The second eluted enantiomer was identified as the title compound ((9S) enantiomer) (97 mg, 48% yield, 99.4% ee). Melting point: 261 ° C The configuration of the analytical method for the HPLC determination of the optical purity was as follows: column: CHIRALPAK® AD 10 μm of 250 x 4.6 mm; mobile phase: n-heptane / ethanol [85: 15 (v / v)]; flow rate: 1.5 ml / min; 35 ° C. The title compound (detection at 220 nm) was eluted after 16.66 min (99.4% ee). Determination of optical purity by EC: TR = 14.9 min / ee 99.4%. Optical rotation: [a] D20 = -30 ° (c = 0.46, chloroform). 1 H NMR (DMSO-d 6, 200 MHz): d = 2.24 (mc, 2 H), 2.57 (s, mc, 4 H), 2.69 (s, 3 H), 2.86 (s, mc, 4 H) ), 3.03 (s, 3 H), 5.35 (dd, 1 H), 7.44 (mc, 5 H), 9, 10 (s, 1 H). B. (9S) -2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid cyclopropylamide 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1, 2-a] pyridine-6-carboxylic acid cyclopropylamide was resolved racemic (example 10, 207 mg, 0.57 mmol) by preparative chromatography using a 5 μm CHIRALPAK® AD-H 250 x 20 mm column. The mobile phase consisted of a mixture of n-heptane and eta-nol [85: 15 (v / v)]. The separation was carried out at room temperature with a flow rate of 20 ml / min. The products were detected at a wavelength of 300 nm. The second eluted enantiomer was identified as the title compound (enantiomer (9S)) (100 mg, 48% yield, ee 99.0-99.5%, the sample contained 10% by weight ethanol). Melting point: 273 ° C The configuration of the analytical method for the HPLC determination of the optical purity was as follows: column: CHIRALPAK® AD 10 μm of 250 x 4.6 mm; mobile phase: n-heptane / ethanol [85:15 (v / v)]; flow rate: 1.0 ml / min; 25 ° C. The title compound (detection at 220 nm) was eluted after 8.14 min (99.1% ee). Determination of optical purity by CE: TR = 16.3 min / ee 99.0%. Optical rotation: [a] D20 = -50 ° (c = 0.56, chloroform). 1 H NMR (dmso-d6) 200 MHz): d = 0.57 (mc, 2 H), 0.70 (mc, 2 H), 1.06 (t, EtOH), 2.06 (mc, 1 H), 2.26 ( s, mc, 4 H), 2.37 (s, 3 H), 2.66-3.08 (m, 3 H), 3.44 (dq, EtOH), 4.32 (t, EtOH), 5.23 (dd, 1 H), 7.42 (mc, 5 H), 7.86 (s, 1 H), 8.42 (d, 1 H). C. (9S) - (2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] - imidazo [1,2- a] pyridin-6-yl) -azetid N-1-yl methanone The resolution of (2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine- Racemic 6-i) -azetidin-1-yl methanone (Example 1, 209 mg, 0.58 mmol) by preparative chromatography using a CH IRALPAK® 50801 20 μm 250 x 50 mm column. Ethanol was used as the mobile phase. The separation was carried out at room temperature with a flow rate of 120 ml / min. The products were detected at a wavelength of 300 nm. The first eluted enantiomer was identified as the title compound ((9S) enantiomer) (1000 mg, 48% yield, ee 100%). Melting point: 248 ° C The configuration of the analytical method for the HPLC determination of the optical purity was as follows: column: CHIRALPAK® 50801 20 μm of 250 x 4.6 mm; mobile phase: ethanol; flow rate: 1.0 ml / min; 30 ° C. The title compound (detection at 220 nm) was eluted after 1 1 .48 min (ee 1 00%). Determination of optical purity by EC: TR = 14.8 min / ee 100%. Optical rotation: [a] D20 = -50 ° (c = 5.50, chloroform). 1 H NMR (dmso-d 6, 200 MHz): d = 2.12, 2.25 (mc, s, 7 H), 2.37 (s, 3 H), 2.66 (mc, 1 H), 2.92 (mc, 1 H) , 4.06 (mc, 4 H), 5.25 (dd, 1 H), 7.42 (mc, 5 H), 7.86 (s, 1 H).

D. (9S) -2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1, 2-a] pyridine-6-carbothioic acid dimethylamide dimethylamide of (9S) -2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide ( 800 mg, 2.29 mmol) and Lawesson's reagent (1.0 g, 2.7 mmol) in 1,2-dimethoxyethane (20 ml) was heated to 50 ° C. After the reaction temperature was reached, the mixture was diluted with more 1,2-dimethoxyethane (15 ml) and stirring was continued for 2 hours at 50 ° C. The reaction was cooled and poured into a mixture of saturated bicarbonate solution (25 ml) and dichloromethane (60 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 10 mL). The combined organic phases were washed with water (2 x 20 ml), dried over sodium sulfate and concentrated under reduced pressure. The residue (1.8 g of a yellow oil) was purified by flash chromatography [15 g of silica gel, eluent: dichloromethane / methanol = 100: 4 (v / v)]. Evaporation of the corresponding fractions yielded an oily residue (750 mg), which was crystallized from acetone (1 ml). After a period of 1 hour, the precipitate was isolated by filtration, washed with acetone (0.5 ml) and diethyl ether (5 ml) and dried under vacuum. The title compound was obtained as a colorless solid (44% yield). Melting point: 244-245 ° C (acetone / diethyl ether) 1 H-NMR (DMSO-d6, 200 MHz): d = 2.12 (mc, 1 H), 2.26, 2.29, 2.34 (s, mc, s, 7 H), 2.63 (mc, 1 H), 2.85 (mc, 1 H), 3.05, 3.17 (2s, 3 H), 3.51, 3.52 (2s, 3 H), 5.26 (mc, 1 H), 7.41 ( mc, 5 H), 7.64, 7.65 (2s, 1 H). lll. Compounds of the formula 1 -b a. (9f?) - 3-acetyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide The resolution of 3-acetyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine acid dimethylamide was carried out 6-racemic carboxylic acid (example 9, 202 mg, 0.54 mmol) as described in Example A. The first eluted enantiomer was identified as the title compound ((9R) enantiomer) (97 mg, 48% yield, ee 99.4 -99.6%). Melting point: 260 ° C The configuration of the analytical method for HPLC determination of optical purity is described in Example A. The title compound (detection at 220 nm) was eluted after 14.38 min (99.6% ee). Determination of optical purity by CE.TR = 15.3 min / ee 99.4%. Optical rotation: [a] D20 = 25 ° (c = 0.46, chloroform). 1 H NMR (dmso-d 6, 200 MHz): d = 2.24 (mc, 2 H), 2.57 (s, mc, 4 H), 2.69 (s, 3 H), 2.86 (s, mc, 4 H) , 3.03 (s, 3 H), 5.35 (dd, 1 H), 7.44 (mc, 5 H), 9.10 (s, 1 H). b. (9 /?) - 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid cyclopropylamide carried out the resolution of the cyclopropylamide of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid racemic (example 10.0, 207 mg, 0.57 mmol) as described in example B. The first eluted enantiomer was identified as the title compound ((9R) enantiomer) (1000 mg, 48% yield, ee). 99.2-99.4%, the sample contained 10% by weight of ethanol). Melting point: 270 ° C The configuration of the analytical method for HPLC determination of optical purity is described in example B. The title compound (detection at 220 nm) was eluted after 6.54 min (ee 99, 2%). Determination of optical purity by CE: TR = 17.0 min / ee 99.4%. Optical rotation: [a] D20 = 35 ° (c = 0.44, chloroform). 1 H NMR (dmso-d 6, 200 MHz): d = 0.57 (mc, 2 H), 0.70 (mc, 2 H), 1.06 (t, EtOH), 2.06 (mc, 1 H), 2, 26 (s, mc, 4 H), 2.37 (s, 3 H), 2.66-3.08 (m, 3 H), 3.44 (dq, EtOH), 4.32 (t, EtOH), 5.23 (dd, 1 H), 7.42 (mc, 5 H), 7.86 (s, 1 H), 8.42 (d, 1 H). c. (9 /?) - (2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2- a] pyridin-6-yl) -azetidin -1-l-methanone The resolution of (2, Racemic 3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1, 2-a] pyridin-6-yl) -azetidin-1-yl methanone (example 1 1, 209 mg, 0.58 mmol) as described in example C. The second eluted enantiomer was identified as the title compound (enantiomer (9R)) (100 mg, 48% yield, 99.6% ee ). Melting point: 247 ° C The configuration of the analytical method for HPLC determination of optical purity is described in example C. The title compound (detection at 220 nm) was eluted after 18.93 min (99.6% ee) ). Determination of optical purity by EC: TR = 15.2 min / ee 99.6%. Optical rotation: [a] D20 = 26 ° (c = 0.50, chloroform). 1 H NMR (dmso-d 6, 200 MHz): d = 2.12, 2.25 (mc, s, 7 H), 2.37 (s, 3 H), 2.66 (mc, 1 H), 2.92 (mc, 1 H) , 4.06 (mc, 4 H), 5.25 (dd, 1 H), 7.42 (mc, 5 H), 7.86 (s, 1 H). IV. Starter Compounds and Intermediates Synthesis of intermediates for 7H-8,9-dihydro-pyran [2,3-cl-imidazofl, racemic 2-alpyridines by cross-metathesis i. 2-amino-3-benzyloxy-5-bromo-pyridine 2-amino-3-benzyloxypyridine (85.0 g, 0.42 mol) was dissolved in a 10% aqueous solution of sulfuric acid (1000 ml). The yellow solution was cooled from 0 to 4 ° C and a solution of bromine (80.5 g, 0.50 mol) in acetic acid (276 g, 4.6 mol) was added dropwise over a period of 2 h. A red suspension was obtained which was stirred for 2.5 h at 0 ° C and was then poured onto a mixture of ice water (500 ml) and dichloromethane (1000 ml). A pH value of 8 was adjusted by adding 25% aqueous ammonia solution (ca. 600 ml) to the well-stirred biphasic mixture. The phases were separated and the aqueous phase was extracted with dichloromethane (3 x 500 ml). The combined organic phases were washed with water (400 ml) and dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by flash chromatography [1 kg of silica gel, eluent: petroleum ether / ethyl acetate = 7: 3 (v / v)]. Thus, 96.0 g of the title compound were isolated as a brown solid (81% yield).

Melting point: 109-1 1 0 ° C. 1 H NMR (CDCl 3, 200 MHz): d = 4.73 (bs, 2 H), 5.04 (s, 2 H), 7.08 (d, 1 H), 7.40 (mc, 5 H), 7.73 (d, 1 H). ii. 8-Benzyl I oxy-6-bromo-2-methyl-imidazo [1,2-a] pyridine A well-stirred solution of 2-amino-3-benzyloxy-5-bromo-pyridine (96.0 g, 0.34 mol) and chloroacetone (50 ml, 58.0 g, 0.63 mol) in dry THF (300 ml) was heated at 60 ° C. After 3.5 days, the precipitate formed in the course of the reaction was removed by filtration, washed with THF (30 ml), and dried under vacuum. The mother liquor was treated with more chloroacetone (50 ml, 58.0 g, 0.63 mol) and the reaction mixture was stirred at 60 ° C for another 8 days. More precipitate formed which was again isolated by filtration, washed with THF (30 ml), and dried under vacuum. The two crops (55 + 48 g) were combined and crystallized from hot isopropanol (800 ml). The colorless crystals obtained (55 g) were dissolved in a biphasic mixture of water and dichloromethane. The mixture was neutralized by the addition of a 6N aqueous solution of sodium hydroxide. The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 50 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The solid obtained was purified by flash chromatography [1.7 kg of silica gel, eluent: petroleum ether / ethyl acetate = 8: 2 (v / v)]. The mother liquor from the crystallization step was concentrated and the residue (48 g) was purified as described above. A total amount of 63.7 g (59% yield) was isolated from a sticky yellow solid, which was the pure title compound as indicated in 1 H-NMR analysis. 1 H NMR (CDCl 3, 200 MHz): d = 2.43 (s, 3 H), 5.28 (s, 2 H), 6.52 (d, 1 H), 7. 37 (mc, 6 H), 7.79 (d, 1 H). iii. 8-benzyloxy-2-methyl-imidazo [1, 2-a] pyridine-6-carboxylic acid dimethylamide A solution of 8-benzyloxy-6-bromo-2-methyl-imidazo [1,2-a] pyrid Na (146.0 g, 0.46 mol) in dry THF (31) was transferred to an autoclave. After the addition of palladium acetate (1 1 .5 g, 0.05 mol), triphenylphosphine (71.0 g, 0.27 mol), triethylamine (1 32 ml, 0.94 mol), and a 2 M solution of dimethylamine in TH F (1.2 l, 2.4 mol), the autoclave was pressurized with carbon monoxide (6 bar) and heated to 120 ° C. After a reaction time of 18 hours the reaction mixture was cooled, filtered, and concentrated under vacuum. The residue was dissolved in dichloromethane (700 ml) and water (300 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (100 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. A tacky brown residue (219 g) was obtained which was purified by flash chromatography (4.4 kg of silica gel, eluent: ethyl acetate, then ethyl acetate / methanol = 9: 1). The title compound was isolated as a beige solid (1 10 g, 77% yield), pure according to 1 H-NMR spectroscopy. 1 H NMR (CDCl 3, 200 MHz): d = 2.47 (s, 3 H), 2.95 (bs, 6 H), 5.35 (s, 2 H), 6.43 (d, 1 H), 7.40 (mc, 6 H), 7.88 (d, 1 H). iv. 8-hydroxy-2-methyl-imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide A solution of 8-benzyloxy-2-methyl-imidazo [1,2-a] pyridin-6-dimethylamide carboxylic acid (58.0 g, 0.19 mol) in methanol (500 ml) was treated with the hydrogenation catalyst (palladium 10% on carbon, 7 g) and a hydrogen pressure of 1 bar was applied. After the suspension had been stirred for 18 hours at room temperature, the catalyst was removed by filtration and the filtrate was concentrated under vacuum. The title compound (40.1 g, 98% yield) was isolated as a beige solid. 1 H-NMR (CDCl 3, 200 MHz): d = 2.44 (s, 3 H), 3.10 (bs, 6 H), 6.74 (d, 1 H), 7.31 (s, 1 H), 7.89 (d, 1 H ), 8.96 (bs, 1 H). v. 8-allyloxy-2-methyl-imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide The 8-hydroxy-2-methyl-imidazo acid dimethylamide [1], 2-a] pyridine-6-carboxylic acid (4.74 g, 21.6 mmol) was dissolved in dry DMF (50 mL). Potassium carbonate (2.98 g, 21.6 mmol) and allyl bromide (3.14 g, 25.9 mmol) were added and the reaction mixture was stirred at room temperature for 8.5 hours. The solvent was removed under reduced pressure and the residue was dissolved in saturated solution of ammonium chloride (100 ml) and chloroform (150 ml). The phases were separated and the aqueous phase was extracted with chloroform (2 x 150 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The dark brown liquid obtained (8.5 g) was purified by flash chromatography [250 g of silica gel, eluent: ethyl acetate / methanol = 4: 1 (v / v)]. The title compound was isolated in 70% yield (5.05 g) as a yellowish oil. Visible traces of impurities (approximately 5 mol-%) were visible in the 1 H-NMR spectrum. 1 H NMR (CDCl 3, 200 MHz): d = 2.46 (s, 3 H), 3.09 (s, 6 H), 4.79 (dt, 2 H), 5.33 (dd, 1 H), 5.45 (dd, 1 H), 6.15 (ddt, 1 H), 6.48 (d, 1 H), 7.33 (s, 1 H), 7.87 (d, 1 H). saw. 7-allyl-8-hydroxy-2-methyl-imidazo [1, 2-a] pyridine-6-carboxylic acid dimethylamide A flask containing dimethylamide of 8-allyloxy-2-methyl-midazo [1, 2-a] ] net pyridine-6-carboxylic acid (3.93 g, 15.2 mmol) was placed in an oil bath, which had been preheated to 160 ° C. After a period of 50 minutes at 160 ° C, the reaction mixture solidified to form a dark brown solid. The crude product was cooled to room temperature and treated with a mixture of acetone and diethyl ether [1: 1 (v / v), 20 ml]. A colorless solid precipitated, which was separated by filtration, washed with diethyl ether (10 ml), and dried under vacuum. Thus, 2.1 g of the pure title compound were isolated. The mother liquor was concentrated under reduced pressure and purified by flash chromatography (70 g of silica gel, eluent: ethyl acetate / methanol = 9: 1 then 4: 1 '(v / v)] yielding another 0.48 g of the title compound. titer (2.58 g, 66% overall yield) 1 H-NMR (CDCl 3, 200 MHz): d = 2.43 (s, 3 H), 2.88 (s, 3 H), 3.1 1 (s, 3 H), 3.55 (bd, 2 H), 5.00, 5.07 (2 dd, 2 H), 5.98 (mC) 1 H), 7.22 (s, 1 H), 7.53 (s, 1 H), 9.57 (bs, 1 H). vii. [7-allyl-6-dimethylcarbamoyl-2-methyl-imidazo [1, 2-a] pyridin-8-yl] ester of pivaloic acid To a 7-allyl-8-hydroxy-2-methyl dimethylamide suspension -imidazo [1,2-a] pyridine-6-carboxylic acid (1.00 g, 3.9 mmol) in acetone (30 ml), potassium carbonate (0.53 g, 3.9 mmol) and pivaloyl chloride (0.93 g, 7.7 mmol). The yellow suspension was stirred for 3 hours at room temperature. After the addition of saturated ammonium chloride solution (20 ml) and water (10 ml), the reaction mixture was extracted with dichloromethane (3 x 50 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The crude product (1.46 g of a colorless solid) was purified by flash chromatography (30 g of silica gel, eluent: ethyl acetate). The title compound was obtained with 72% yield (0.96 g). Melting point: 178-180 ° C. 1 H-NMR (CDCl 3, 200 MHz): d = 1.48 (s, 9 H), 2.41 (s, 3 H), 2.89 (s, 3 H), 3.08 (s, 3 H), 3.35 (d, 2 H), 5.04 (mc, 2 H), 5.78 (mc, 1 H), 7.28 (s, 1 H), 7.82 (s, 1 H). viii. (E) - [6-dimethylcarbamoyl-2-methyl-7- (3-phenyl-allyl) -imidazo [1, 2-a] pyridin-8-yl] ester of pivaloic acid [7-allyl] ester was dissolved 6-dimethylcarbamoyl-2-methyl-imidazo [1, 2-a] pyridin-8-yl] of pivaloic acid (9.30 g, 27.1 mmol) in dichloromethane (140 ml), which had been degassed with argon. After the addition of frans-stilbene (1 9.53 g, 1 08.4 mmol) and second generation Grubbs catalyst (CAS 246047-72-3, 920 mg, 1.08 mmol, 4 moI-%) a red solution was obtained . The reaction mixture was heated to 40 ° C and was stirred for 1 8 hours at this temperature. The crude product obtained by concentration of the green solution was purified by flash chromatography [1]., 2 kg of silica gel, eluent: petroleum ether (to remove excess frans-stilbene), then ethyl acetate]. A slightly green solid (6.6 g) was isolated consisting of the title compound (90 mol-%, 53% yield) and untransformed starting material (10 mol-%, proportion determined by 1 H-NMR analysis) . 1 H-NMR data of the title compound, derived from a 9: 1 mixture with untransformed starting material (CDCl 3, 200 MHz): d = 1.49 (s, 9 H), 2.42 (s, 3 H), 2.79 (s, 3 H), 3.01 (s, 3 H), 3.53 (d, 2 H), 6.12 (dt, 1 H), 6.43 (d, 1 H), 7.24 (mc, 6 H), 7.81 (s) , 1 HOUR). The NMR signals of the starting material were previously reported. ix. 2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide The product of the cross-metathesis reaction (example viii, 6.6 g), containing (E) - [6-dimethylcarbamoyl-2-methyl-7- (3-phenyl-allyl) -imidazo [1, 2-a] pyridin-8-yl ester] of pivaloic acid (6.5 g, 14 mmol) and [7-allyl-6-dimethylcarbamoyl-2-methyl-imidazo [1, 2-a] pyridin-8-yl] ester of pivaloic acid (0.5 g, 1. mmol) was treated with 200 ml of orthophosphoric acid (85%). The resulting green solution was heated for 50 minutes at 80 ° C. The reaction mixture was cooled to room temperature, diluted with dichloromethane (200 ml), and neutralized with a 6N sodium hydroxide solution at 0 ° C. The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 200 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash chromatography [21.0 g of silica gel, eluent: ethyl acetate / methanol = 9: 1 (v / v)]. A colorless solid was obtained (4.4g, 91% yield), which was the pure title compound as indicated by 1 H-NMR analysis. Melting point: 1 89 ° C 1 H-NMR (CDCU, 200 MHz): d = 2.6 (mc, 2 H), 2.41 (s, 3 H), 2.58. 2.77 (2 mc, 2 H), 2.94 (s, 3 H), 3.12 (s, 3 H), 5.31 (dd, 1 H), 7.40 (m0, 6 H), 7.67 (s, 1 H). x. 2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide prepared by synthesis in a container The title compound it can also be obtained by applying a process in a container: in a flame-dried flask filled with argon, [7-allyl-6-dimethylcarbamoyl-2-methyl-imidazo [1,2-a] pyridine ester was dissolved. -8-yl] of pivaloic acid (example vii, 4.80 g, 14.0 mmol) in dichloromethane (100 ml) which had been degassed with argon. After addition of frans-stilbene (10.10 g, 56.0 mmol) and second generation Grubbs catalyst (CAS 246047-72-3, 475 mg, 0.56 mmol, 4 mol-%) the solution was heated to 40 ° C. The reaction mixture was stirred for 1 8 hours at this temperature and then concentrated under reduced pressure. A green solid was obtained which was treated with 100 ml of orthophosphoric acid (85%). The suspension was heated to 80 ° C. After a period of 1 hour, a clear solution was obtained which was cooled to room temperature and poured onto a mixture of ice water (50 ml) and dichloromethane (50 ml). A pH value of 8 was adjusted by addition of 6N sodium hydroxide solution. The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 20 ml). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The residue, 16 g of a green solid, was purified by flash chromatography [320 g of silica gel, eluent: petroleum ether (to remove excess rans-stilbene), then ethyl acetate / methanol = 100: 2 ( v / v)]. The title compound (3.0 g, 64% yield) was isolated as a green, foamy solid, pure according to 1 H-NMR spectroscopy. 1 H-NMR (CDCl 3, 200 MHz): d = 2.26 (mc, 2 H), 2.41 (s, 3 H), 2.58. 2.77 (2 mc, 2 H), 2.94 (s, 3 H), 3.12 (s, 3 H), 5.31 (dd, 1 H), 7.40 (mc, 6 H), 7.67 (s, 1 H). xi. 3-formyl-2-methyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide A flask containing dry DMF ( 12 ml) was cooled to 0 ° C and phosphorus oxychloride (0.914 g, 5.96 mmol) was added. The cooling bath was removed and the solution was stirred for 1 hour at room temperature. The red reaction mixture was treated with a solution of 2-methyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] imidazo [1,2-a] pyridin-6-dimethylamide. carboxylic acid (0.800 g, 2.39 mmol) in dry DMF (12 ml) and heated to 60 ° C. After a period of 5 hours, the reaction mixture was poured onto ice water (10 ml), neutralized by addition of 6N sodium hydroxide solution, and then extracted with dichloromethane (3 x 20 ml). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. 13 was obtained compound of the title (0.700 g, 81% yield) as a yellow solid, pure according to 1 H-NMR spectroscopy. 1 H NMR (CDCl 3, 200 MHz): d = 2.31 (mc, 2 H), 2.72 (s, mc, 4 H), 2.89, 2.95 (mc, s, 4 H), 3.15 (s, 3 H) , 5.34 (dd, 1 H), 7.39 (mc, 5 H), 9.09 (s, 1 H), 9.99 (s, 1 H). xii. 2-methyl-3-nitroso-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide In a flask dried at flame filled with argon, a solution of dimethylamide of 2-methyl-9-phenyI-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid (example ix, 0.70 g, 2.1 mmol) in dry THF (15 ml) was treated with isopentyl nitrite (2.44 g, 20.8 mmol). The reaction mixture was stirred for 2.5 hours at 40 ° C and then concentrated under vacuum. The dark crude product was purified by flash chromatography (16 g of silica gel, eluent: ethyl acetate). Evaporation of the corresponding fractions yielded the title compound as a green foamy solid (0.56 g, 74% yield). 1 H-NMR (CDCIs, 200 MHz): d = 2.32 (mc, 2 H), 2.83, 2.92 (mc, s, 5 H), 3.15, 3.16 (2 s, 6 H), 5.37 (dd, 1 H) , 7.39 (mc, 5 H), 9.37 (s, 1 H), additional signs to 7.1 0 (d) and 7.94 (d). Synthesis of intermediates for racemic 7H-8,9-dihydro-pyran [2,3-c1-imidazof1,2-alpyridines by saponification of 2,3-dimethyl-9-phenyl-7H-8,9- ethyl ester dihydro-pyrano [2,3-cJ-imidazo1,2,2-a1pyridine-6-carboxylic acid: xiii. 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid A suspension of 2,3- ethyl dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1, 2-a] pyridine-6-carboxylate (synthesis described in WO 03/014123, 1 6.7 g, 48 mmol) in methanol (170 ml) and water (35 ml) was treated with potassium hydroxide (4.5 g, 80 mmol) and heated to 50 ° C. After a reaction time of 2 hours, the methanol was removed under vacuum. Water (400 ml) and dichloromethane (300 ml) were added, a pH value of 4.8 was adjusted (isoelectric point of the title compound) by addition of 6N hydrochloric acid, and stirring was continued for 30 minutes. A precipitate formed, which slowly dissolved after the addition of dichloromethane (100 ml) and methanol (1000 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 50 ml). The combined organic phases were dried over sodium sulfate and concentrated to a volume of 50 ml. With the addition of diethyl ether (100 ml) a colorless precipitate formed. Stirring was continued for 30 minutes at 0 ° C. The precipitate was separated by filtration and dried under vacuum yielding 9.1 g of pure title compound (58% yield). The aqueous phase was saturated with sodium chloride and extracted with chloroform (1 x 400 ml, 2 x 100 ml). The combined organics were dried over sodium sulfate and concentrated under vacuum. The residue (2.0 g, 13% yield) was the pure title compound according to 1 H-NMR spectroscopy. Melting point: 31-8-320 ° C (diethyl ether) 1 H-NMR (dmso-d6, 200 MHz): d = 2.09 (mc, 1 H), 2.28 (s, mc, 4 H), 2.40 (s) , 3 H), 3.10 (mc, 2 H), 5.25 (dd, 1 H), 7.43 (mc, 5 H), 8.32 (s, 1 H), interchangeable patterns not visible. Elemental analysis: calculated for C19H18N2? 3. (H2O) o.5 (322.37 + 9.0): C 68. 87, H 5.78. N 8.45; found: C 68.95, H 5.49, N 8.40. xiv. 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid (2-hydroxyethyl) -amide A mixture of 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (0.50 g, 1.6 mmol) ) and thionyl chloride (0.34 ml, 0.55 g, 4.6 mmol) was diluted with dry dichloromethane (7 ml). The suspension was treated with DBU (0.24 ml, 0.24 g, 1.6 mmol) and was stirred for 24 hours at room temperature. The clear brown reaction mixture was evaporated to dryness and the residue was dissolved in dry dichloromethane (15 ml). The resulting suspension was cooled to 0 ° C and a solution of 2-aminoethanol (0.17 ml, 0.17 g, 2.8 mmol) in dichloromethane (5 ml) was added. The reaction mixture was stirred for 2.5 hours at room temperature. The precipitate was separated by filtration. The filtrate was concentrated under vacuum and the brown residue (0.9 g) was purified by flash chromatography [36 g of silica gel, eluent: ethyl acetate / methanol = 10: 1 (v / v)]. Evaporation of the corresponding fractions yielded the pure title compound (0.25 g of a colorless solid, 44% yield). 1 H-NMR (CDCl 3, 200 MHz): d = 1.92 (mc), 2.27 (mc, s, 4 H), 2.41 (s, 3 H), 2.68 (mc, 2 H), 3.46 (mc, 2 H), 3.71 (mc, 2 H), 4.97 (dd, 1 H), 7.14 (bt, 1 H), 7.27 (s), 7.42 (mc, 5 H). xv. 2,3-Dimethyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid (2-chloroethyl) -amide A solution 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] imidazo [1,2-a] pyridine-6-carboxylic acid (2-hydroxyethyl) -amide ( 0.30 g, 0.8 mmol) in thionyl chloride (0.40 ml, 0.65 g, 5.5 mmol) was stirred for 1 hour at room temperature. It was then diluted with dichloromethane (30 ml) and water (5 ml) and a neutral pH value was adjusted by the addition of saturated sodium bicarbonate solution. The phases were separated and the aqueous phase was extracted with dichloromethane (20 ml). The combined organic phases were dried over sodium sulfate, concentrated under reduced pressure, and dried under vacuum. The title compound was obtained in 70% yield (0.22 g of a colorless solid). 1 H-NMR (CDCl 3, 200 MHz): d = 2.14 (mc), 2.32, 2.38 (2 s, mc, 7 H), 2.85 (mc, 1 H), 3.08 (mC) 1 H), 3.75 (s, 4 H), 5.21 (dd, 1 H), 6.90 (bs, 1 H), 7.36 (mc, 5 H), 7.60 (s, 1 H). xvi. 2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pYrano [2,3-c] -imidazo [1, 2-a] pyridine-6-carboxylic acid amide A suspension of acid 2 , 3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridine-6-carboxylic acid (example xiii, 500 mg, 1.54 mmol ) in dichloromethane (20 ml) was treated with TBTU (504 mg, 1.57 mmol). The reaction mixture was heated for 1 hour at 40 ° C and. then it was allowed to cool to room temperature. Ammonia gas was bubbled through the suspension for a period of 30 minutes. The reaction mixture was poured into water (20 ml), dichloromethane (30 ml) was added, and a pH value of 6 was adjusted by the addition of 2N hydrochloric acid. In order to facilitate phase separation, a 1 ml portion of methanol was added. The phases were separated, and the aqueous phase was extracted with dichloromethane (2 x 10 ml). The combined organic phases were dried over sodium sulfate and concentrated under vacuum. The title compound (310 mg, 64% yield) was isolated as a colorless, pure solid according to 1 H-NMR spectroscopy. Melting point: 303-305 ° C 1 H-NMR (dmso-de, 200 MHz): d = 2.09 (mc, 1 H), 2.26 (mc, s, 4 H), 2.38 (s, 3 H), 2.97 (mc, 2 H), 5.24 (dd, 1 H), 7.41 (bs, mc, 6 H), 7.85 (bs, 1 H), 7.98 (s, 1 H). Asymmetric Hydroboration of Prochiral Olefins xvii. (£) -8-Hydroxy-2-methyl-7- (3-phenyl-allyl) -imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide (£) - [6-dimethylcarbamoyl] ester -2-methyl-7- (3-phenyI-allyl) -imidazo [1, 2-a] pyridin-8-yl] of pure pivaloic acid (synthesis as described in example viii) in methanol (200 ml ). After the dropwise addition of a 6N sodium hydroxide solution (12 ml), the reaction mixture was stirred for 1 hour at room temperature and for another hour at 50 ° C. The dark solution was concentrated to a volume of 30 ml. Water (30 ml) and dichloromethane (50 ml) were added and the biphasic mixture was neutralized by addition of 6N hydrochloric acid. The phases were separated and the aqueous phase was extracted with dichloromethane (3 x 15 ml). The combined organic phases were washed with water (20 ml), dried over sodium sulfate, and evaporated to dryness. A dark solid (5 g) was obtained, which was dissolved in a hot mixture of dichloromethane (20 ml) and acetone (60 ml). The stirred solution was allowed to cool to room temperature, at which point the crystallization took place. Stirring was continued for 1 hour at room temperature. The precipitate was isolated by filtration, washed with diethyl ether (10 mL) and dried under vacuum. The title compound was isolated as a colorless solid (2.6 g, 55% yield). Melting point: 188-190 ° C (dichloromethane / acetone) 1 H-NMR (dmso-de, 200 MHz): d = 2.35 (s, 3 H), 2.75 (s, 3 H), 2.94 (s, 3 H), 3.48 (d, 2 H), 6.28 (mc >; 2 H), 7.26 (mc, 5 H), 7.59 (s, 1 H), 7.97 (s, 1H). xviii. (3 /?) - 8-hydroxy-7- (3-hydroxy-3-phenyl-propyl) -2-methyl-imidazo [1, 2-a] pyridine-6-carboxylic acid dimethylamide A flame-dried flask filled with argon was charged with (R) -Alpine-boramine ™ (CAS 67826-92-0, 1.50 g, 3.6 mmol). After the addition of dry THF (8 ml), a colorless solution was obtained, which was treated with boron trifluoride diethyl ether (0.92 ml, 1.03 g, 7.3 mmol). The solution was stirred for 2.5 hours at room temperature and for 1 hour at 0 ° C. A colorless precipitate was obtained which was separated by filtration and washed with cold THF (6 ml, argon atmosphere). The filtrates were combined [containing (-) - monoisopinocamfeylborane]. A suspension of 8-hydroxy-2-methyl-7- (3-phenyl-allyl) -imidazo [1,2-a] pyridine-6-carboxylic acid dimethylamide (405 mg, 1.21 mmol) in THF was added. dry (15 ml) at room temperature, at which point a yellow solution was obtained. After a reaction time of 2 hours, the solution was slowly added to a cold mixture of potassium hydroxide solution (230 mg in 1.6 ml of water), ethanol (4 ml), and hydrogen peroxide (30%). weight in water, 1.6 ml). After a period of 15 minutes, the reaction mixture was poured into saturated solution of ammonium chloride (20 ml) and dichloromethane (40 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 10 mL). The combined organic phases were washed with water (10 ml), dried over sodium sulfate, and concentrated under reduced pressure. The crude product (1.7 g of an oil) was purified by flash chromatography [20 g of silica gel, eluent: dichloromethane (to remove isopino-camfeol), then dichloromethane / methanol = 20: 1 (v / v) ] Evaporation of the corresponding fractions gave a solid (220 mg), which was washed with acetone (1 ml), isolated by filtration, and dried under vacuum. The title compound was isolated in 18% yield (75 mg of a colorless solid, optical purity: 32.2% ee). Melting point: 223-224 ° C (acetone) Determination of optical purity by EC: TR [enantiomer (3S)] = 1 7.6 min / 33.2 area-%; TR [enantiomer (3R)] = 17.8 min / 64.8 area-%; ee 32.2% (A). 1 H-NMR (dmso-de, 200 MHz): d = 1.81 (mc, 2 H), 2.33 (s, mc, 4 H), 2.65 (mc), 2.77, 2.89 (2 s, 6 H) , 4.50 (t, 1 H), 7.25 (mC) 5 H), 7.55 (s, 1 H), 7.88 (s, 1 H). Commercial utility The compounds of formula 1 and their salts have valuable pharmacological properties that make them commercially useful. In particular, they exhibit marked inhibition of gastric acid secretion and an excellent gastric and intestinal protective action in warm-blooded animals, in particular humans. In this context, the compounds according to the invention are distinguished by a high selectivity of action, an advantageous duration of action, particularly a good enteral activity, absence of significant side effects and a wide therapeutic range. "Gastric and intestinal protection" in this context is understood to mean the prevention and treatment of gastrointestinal diseases, in particular of gastrointestinal inflammatory diseases and lesions (such as, for example, gastric ulcer, peptic ulcer, including bleeding peptic ulcer, ulcer duodenal, gastritis, hyperacid functional dyspepsia or drug-related dyspepsia), which may be caused, for example, by microorganisms (eg, Helicobacter pylo-ri), bacterial toxins, drugs, (eg, certain anti-inflammatory and anti-rheumatic drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) and COX inhibitors), chemical agents (for example, ethanol), gastric acid or stress situations. It is understood that "Gastric and intestinal protection" includes, according to general knowledge, esophageal reflux disease (GERD), whose symptoms include, but are not limited to, acidity and / or acid regurgitation. In its excellent properties, the compounds according to the invention surprisingly prove to be clearly superior to the compounds known in prior art in several models in which the antiulcerogenic and antisecretory properties are determined. Based on these properties, the compounds of formula 1 and their pharmacologically acceptable salts are remarkably suitable for use in human and veterinary medicine, where they are used in particular, for the treatment and / or prophylaxis of disorders of the stomach and / or intestine . A further object of the invention are, accordingly, the compounds according to the invention for use in the treatment and / or prophylaxis of the aforementioned diseases. The invention similarly includes the use of the compounds according to the invention for the production of medicaments that are used for the treatment and / or prophylaxis of the aforementioned diseases. The invention further includes the use of the compounds according to the invention for the treatment and / or prophylaxis of the aforementioned diseases. A further object of the invention are medicaments comprising one or more compounds of formula 1 and / or their pharmacologically acceptable salts. The drugs are prepared by methods that are known per se and familiar to the person skilled in the art. As medicaments, the pharmacologically active compounds according to the invention (= active compounds) are used as such, or preferably in combination with pharmaceutical auxiliaries or excipients in the form of tablets, coated tablets, capsules, suppositories, patches (e.g. as TTS), emulsions, suspensions or solutions, the content of active compound being between 0.1 and 95% and it being possible to obtain a pharmaceutical administration form exactly adapted to the active compound and / or at the desired beginning and / or duration of the action (by example, a sustained release form or an enteric form) through the appropriate selection of auxiliaries and excipients. The auxiliaries and excipients that are suitable for the desired pharmaceutical formulations are known to the person skilled in the art based on their expert knowledge. In addition to the solvents, gel forming agents, suppository bases, tablet auxiliaries and other excipients of the active compounds, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor correctors, preservatives, solubilizers, dyes or, in particular, permeation promoters and complexing agents (for example cyclodextrins). The active compounds can be administered orally, parenterally or percutaneously. In general, it has proven advantageous in human medicine to administer the active compounds in the case of oral administration in a daily dose of from about 0.01 to about 20, preferably 0.05 to 5, in particular 0.1 to 1.5 mg / kg of weight body, if appropriate in the form of several, preferably 1 to 4, individual doses to achieve the desired result. In the case of a parenteral treatment, in a similar manner or (in particular in the case of intravenous administration of the active compounds), as a rule, lower doses may be used. The establishment of the optimal dosage and form of administration of the active compounds, necessary in each case, can be easily carried out by any person skilled in the art on the basis of his expert knowledge. If the compounds according to the invention and / or their salts are to be used for the treatment of the aforementioned diseases, the pharmaceutical preparations may also contain one or more pharmacologically active constituents of other drug groups, for example: tranquilizers (eg example of the benzodiazepine group, for example diazepam), spasmolytics (for example, bietamiverine or camilofina), anticholinergics (for example oxifenci-climina or fencarbamida), local anesthetics (for example, tetracaine or procaine) and, if appropriate, also enzymes, vitamins or amino acids. To be emphasized in this context is, in particular, the combination of compounds according to the invention with pharmaceutical agents that inhibit acid secretion, such as, for example, H2 blockers (eg, cimetidine, ranitidine), ATPase H + inhibitors. / K + (for example omeprazole, pantoprazole), or in addition the so-called peripheral anticholinergics (for example "pirenzepine, telenze-pina) and with gastrin antagonists in order to increase the main action in an additive or super-additive sense and / or to eliminate or diminish the side effects, or additionally the combination with antibacterial active substances (such as, for example, cephalosporins, tetracyclines, penicillins, macrolides, nitroimidazoles or alternatively bismuth salts) for the control of Helicobacter pylori. Suitable antibacterial components that may be mentioned are, for example, mezlocillin, ampicillin, amoxicillin, cephalothin, cefoxitin, c efotaxime, imipenem, gentamicin, amikacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (for example clarithromycin + metronidazole). In view of their excellent gastric and intestinal protective action, the compounds of formula 1 are suitable for a free or fixed combination with those medicaments (for example, certain anti-inflammatory and anti-rheumatic drugs, such as NSAI D), which are known to There is a certain ulcerogenic power. In addition, the compounds of formula 1 are suitable for a free or fixed combination with motility modifying drugs. Pharmacology The excellent gastric protective action and action of inhibiting the gastric secretion of the compounds according to the invention can be demonstrated in investigations in experimental animal models. The compounds of formula 1 according to the invention investigated in the model mentioned below have been numbered corresponding to the numbers of those compounds in the examples. Testing the action of inhibiting the secretion in perfused rat stomach In Table A below, the influence of the compounds of the formula 1 according to the invention on the secretion of acid stimulated by pentagastrin, of the rat stomach is shown perfused after intraduodenal administration in vivo.

Table A In Table B below, the influence of the compounds of the formula 1-a according to the invention and their optical antipodes of the formula 1-b on the secretion of acid stimulated by penta-gastrin of the perfused rat stomach is shown after intraduodenal administration in vivo. Table B Methodology The abdomen of anesthetized rats (CD rats, females, 200-250 g, 1.5 g / kg urethane im) was opened after tracheotomy through a medium upper abdominal incision and a PVC catheter was transorally fixed in the esophagus and another through the pylorus so that the ends of the tubes are hardly projected into the gastric lumen. The catheter that led from the pylorus led outward into the right abdominal wall through a lateral opening. After complete rinsing (approximately 50-100 ml), physiological solution of warm NaCl (37 ° C) was continuously passed through the stomach (0.5 ml / min, pH 6.8-6.9, Braun Unita I). The pH (pH meter 632, glass electrode EA 147, f = 5 mm, Metrohm) and, by titration with 0.01 N solution of freshly prepared NaOH were determined in the effluent in each case collected at 15 minute intervals. pH 7 (Dosimat 665 Metrohm) the segregated HCl. Gastric secretion was stimulated by continuous infusion of 1 μg / kg (= 1.65 ml / h) of pentagastrin i.v. (left femoral vein) approximately 30 min after the end of the operation (ie after the determination of 2 preliminary fractions). The substances to be tested were administered intraduodenally in a liquid volume of 2.5 ml / kg, 60 min after the start of the continuous infusion of pentagastrin. The body temperature of the animals was maintained at about 37.8-38 ° C constant by infrared irradiation and heating pads (automatic control, without steps by means of a rectal temperature sensor).

Claims

1. A compound of formula 1 wherein R1 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl, C1- 4-alkoxycarbonyl, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or hydroxy-C1-4-alkyl, R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3- 7-cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, hydroxy-C 1-4 -alkyl, hydroxy-C 3-4 -alkenyl, hydroxy-C 3-4 -alkynyl, halogen, C 2-4 -alkenyl, C 2- 4-alkynyl, fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonyl, C 1-4 -alkoxycarbonyl, C1-4-C 1-4 alkoxy-alkoxycarbonylamino, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, d-7-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridind "or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4 -alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxycarbonyl, fluo-ro-C1-4-alkoxy-C1-4-alkyl, cyano , the radical -CO-NR31 R32, the radical -SO2-NR31 R32, the radical -CS-NR31 R32, the radical -C = N (OH) -NR1 R32 or the group Het wherein R31 is hydrogen, amino, C1 -7-alkyl, hydroxyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-4 -alkylsulfonyl, aryisulphonyl, aryl-C 1 -4-alkylsulfonyl or aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidi no, piperidino, piperazino, morpho-flax, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole , and tetrazole wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, - boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, arii-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino , mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4-alkyl, C1- 4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, Arom is an aromatic substituted radical with R4, R5, R6 and R7 mono- or bicyclic, selected from the group consisting of phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furanyl (furyl), benzofuranyl (benzofuryl), thiophenyl ( thienyl), benzothiophenyl (benzothienyl), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl, wherein R 4 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 2-4 -alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4 -alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1- 4-alkoxycarbonylamino or sulfonyl, R5 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R6 is hydrogen, C1-4alkyl or halogen and R7 is hydrogen, C1-4-alkyl or halogen, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro , trifluoromethoxy, hydroxyl and cyano, with the proviso that, when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy C1-4-alkyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alky1 or cyanomethyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31R32, the radical

-SO2-NR31R32, the radical -CS-NR31R32, the radical -C = N (OH) -NR1R32 or the group Het wherein for the radical -CO-NR31R32 R31 is amino, hydroxyl, C1-4-alkoxy, C3- 7-cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -aniquid, C 1-4 -alkoxy-C 1-4- alkyl or C3-7-cycloalkyl, and for the radicals -SO2-NR31R32, -CS-NR31R32, and -C = N (OH) -NR1R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-G1- 4-alkyl, C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl or aryl and R32 is hydrogen , C 1 -7-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached united form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino as a in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R 33 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 2-4 -alkenyloxy , C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl , aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4- alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4alkyl, C1-4alkoxy, C1- 4-akoxycarbonyl, halogen, trifluoromethyl or hydroxyl, and their salts. 2. A compound of formula 1 as claimed in claim 1, wherein R1 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1- 4-alkoxy, C 1-4-C 1-4 alkoxy-alkyl, C 1-4-alkoxycarbonyl, C 2-4-alkenyl, C 2-4-alkynyl, fluoro-C 1-4 -alkyl or hydroxy-C 1-4 -alkyl, R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl, cyanomethyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4 -alkyl, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4 -alkoxycarbonylamino, carboxyl, mono- or di-C 1-4 -alkylamino-C 1-4 -alkyl, C 1-4- alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynecarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4 -alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1 -7-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R 3 is hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkoxy-C 1-4- alkyl, C 1-4 alkoxycarbonyl, fluoro-C 1-4-C 1-4 alkoxy-alkyl, an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO-NR 31 R 32, wherein R 31 is hydrogen, C 1-7 alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy- C 1-4 alkyl or C 3-7 cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, Arom is an aromatic radical substituted with R 4 , R5, R6 and R7 mono- or bicyclic, selected from the group consisting of phenyl, naphthyl or, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furanyl (furyl), benzofuranyl (benzofuryl), thiophenyl (thienyl), benzothiophenyl (benzothienyl), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl , wherein R4 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi -C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono - or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R5 is hydrogen, C1-4-alkyl, C1-4 -alkoxy, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 6 is hydrogen, C 1-4 -alkyl or halogen and R 7 is hydrogen, C 1-4 -alkyl or halogen, wherein aryl is phenyl or substituted phenyl having one , two ot substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, with the proviso that, when R 2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, halogen, C2-4-alkenyl, C2 -4-alkynyl, fluoro-C 1-4 alkyl or cyanomethyl, then R 3 is an imidazolyl, tetrazolyl or oxazolyl radical or the radical -CO- NR 31 R 32, wherein R 31 is C 3-7 -cycloalkyl and R 32 is hydrogen, C 1 - 7-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a radical aziridino or azetidino, and its salts.

3. A compound of formula 1 as claimed in claim 1, wherein R1 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3 -7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, halogen, C2-4-alkenyl, C2 -4-alkynyl, fluoro-C1-4-alkyl, cyanomethyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1- 4-alkoxy-C 1-4 alkoxycarbonylamino, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or the radical- CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7- alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom to which they are attached s form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1- 4-alkoxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, fluo-ro-C 1-4 -alkoxy-C 1-4 -alkyl, cyano, the radical -CO-NR 31 R 32, the radical -SO 2 -NR 31 R 32, the radical -CS-NR31R32, the radical -C = N (OH) -NR1R32 or the group Het wherein R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyI, C1-4-alkoxy, C1-4-C 1-4 alkoxy-C 3-7 alkyl-cycloalkyl, C 1-4 alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfony, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1- 4-alkyl, C 1 -4-alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R 33 , R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, its constituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroxy-dazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1- 4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen , hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C 1-4-alkylamino, C 1-4 -alkylcarbonylamino, C 1-4- alkoxycarbonylamino, C 1-4-alkoxy-C 1-4 alkoxycarbonylamino or sulfonyl, R 34 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C1- 4-alkyl, C 1-4 alkoxy, carboxyl, C 1-4 alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, Arom is a phenyl substituted with R 4 and R 5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) ) where R4 e s Hydrogen or C1-4-alkyl, halogen, C1-4-alkoxy, trifluoromethyl R5 is hydrogen or C1-4-alkyl, halogen with the proviso that, when R2 is hydrogen, C1-4-alkyl, C3-7- cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, halogen, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or cyanomethyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical -CS-NR31R32, the radical -C = N (OH) -NR1R32 or the group Het in where for the radical -CO-NR31R32 R31 is amino, hydroxyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, and for the radicals -SO2-NR31R32, -CS-NR31R32, and -C = N (OH) -NR1R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl , C1-4- alquilsul fonilo, arisulphonyl, aryl-C 1 -4-alkylsulfonyl, aryl and R32 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl , or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R 33 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 2-4 -alkenyloxy , C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl or, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1 -4-alkoxycarbonylamino, C 1-4-alkoxy-C 1-4 alkoxycarbonylamino or sulfonyl, R 34 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen , C 1-4 -alkyl, C 1-4-alkoxy, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of -4-alkyl, C1-4-alkoxy, carboxyl, C1-4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts.

4. A compound of formula 1 as claimed in claim 1, wherein R1 is hydrogen, C1-4-alkyl or C3-7-cycloalkyl, R2 is hydrogen, C1-4-alkyl, hydroxy-C3-4- alkenyl, hydroxy-C3-4-alkynyl, hydroxyl, C1-4-alkoxy, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonyl amine, C 1-4 alkoxycarbonylamino, C 1-4 alkoxy C 1-4 alkoxycarbonylamino, carboxyl, mono- or di-C 1-4 alkylamino-C 1-4 alkyl, C 1-4 alkylcarbonyl, C 2-4 alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R21 and R22 together and including the nitrogen atom to which they are attached form a radical pyrrolidino, piperidino, morpholino, aziridino or azetidino, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy -C1-4-C1-4alkoxy-alkyl, C1-4alkoxycarbonyl, fluo-ro-C1-4-alkoxy-C1-4alkyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32 , the radical -CS-NR31R32, the radical -C = N (OH) -NR1R32 or the group Het wherein R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C1-4-alkyl, C1-4 -alkoxy, C1-4-alkoxy -C1-4-alkyl, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl or aryl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1 -4-C 1-4 alkoxy-C 3-7 alkyl-cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R 33, R 34 and R 35, selected from the group which consists of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, midazole, isoxazole , dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4 -alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4-alkoxy, trifluoromethyl nitro, amino, mon o- or di-C 1-4-alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4 -alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three identical or different substituents from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano , Arom is a phenyl substituted with R 4 and R 5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl R 5 is hydrogen or C 1 - 4-alkyl, halogen with the proviso that, when R2 is hydrogen or C1-4-alkyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31 R32, the radi lime -S02-NR31 R32, the radical -CS-NR31 R32, the radical -C = N (OH) -NR1 R32 or the group Het where for the radical -CO-NR31 R32 R31 is amino, hydroxyl, C1 -4- alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arylsulfonyl, aryl-C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy- C1-4-alkyl or C3-7-cycloalkyl, and for the radicals -SO2-N R31 R32, -CS-N R31 R32, and -C = N (OH) -NR1 R32 R31 is hydrogen, amino, C1 -7 -alkyl, hydroxyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-4 -alkylsulfonyl, aryisulphonyl, arid-C 1-4 -alkylsulfonyl or aryl and R32 is hydrogen, C1 -7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridi no or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected of the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4alkyl, hydroxy-C1-4alkyl, C1-4alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl- C 1-4 -alkyl, aryl-oxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C 1-4-alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4- alkyl, C1-4-alco xi, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts.

5. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4- alkynyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4-alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C 1-4 -alkoxycarbonylamino, carboxyl, mono - or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen, C1- 4-alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl and R 22 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4- 4-alkoxy-C 1-4 alkyl or C 3-7-cycloalkyl, or wherein R 21 and R 22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R 3 is cyano, the radical -CO-NR31 R32, the radical -CS-NR31 R32, or the group Het, wherein R31 is hydrogen, C1- 7-alkyl, C 1-4-alkoxy, C 3-7-cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, or C 3-7 -cycloalkyl , or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1 -4-alkylcarbonyl, C 1-4-alkoxycarbonyl, halogen, hydroxy wherein aryl is phenyl or substituted phenyl having one, two or three identical or different substituents from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1 - 4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, Arom is a phenyl substituted with R4 and R5, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R4 is hydrogen or C1-4-alkyl, halogen , C1-4-alkoxy, trifluoromethyl R5 is hydrogen or C4-4-alkyl, halogen with the proviso that, when R2 is C1-4-alkyl, then R3 is cyano, the radical -CO-NR31 R32, radical -CS-NR31 R32, or the group Het wherein for the radical -CO-NR31 R32 R31 is C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4-alkylsulfonyl , aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, and for the radical -CS-NR31 R32 R31 is hydrogen, C1-7-alkyl, C 1 -4-alkoxy, C3-7- Cycloalkyl, C1 4-alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, or C 3-7 -cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom to which they are attached. united form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholino, aziridi-no or azetidino wherein in the case of pyrrolidino, piperidino, or morpholino, the substituent R33 must be different from hydrogen , and Het is a heterocyclic residue, substituted with R33, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, C1- 4-alkoxy, C 1-4 -alkylcarbonyl, C 1-4 -alkoxycarbonyl, halogen, hydroxyl, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C1-4- alkoxy, carboxyl, C1-4-alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, and their salts.

6. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkenyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21 R22, wherein R21 is hydrogen , C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, R3 is cyano, the radical -CO- NR31 R32, the radical -CS-NR31 R32, or the group Het, wherein R31 is hydrogen, C1-7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl -C1-4-alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino, and Het is a heterocyclic ester, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl , C1-4- alkoxycarbonyl, halogen, hydroxyl wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C1-4alkyl, C1-4alkoxy, C1-4- alkoxycarbonyl, halogen, hydroxyl, Arom is a phenyl substituted with R 4, pyrrolyl, furanyl (furyl), thiophenyl (thienyl) wherein R 4 is hydrogen or C 1-4 -alkyl, halogen, C 1-4 -alkoxy, trifluoromethyl with the proviso that, when R 2 is C 1-4 -alkyl, then R 3 is cyano, the radical -CO-NR 31 R32, the radical -CS-N R31 R32, or the group Het wherein for -CO-NR31 R32 R31 is C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryisulfonyl, aryl-C1-4 -alkylsulfonyl, aryl and R32 is hydrogen, C1-7-alkyl, or C3-7-cycloalkyl, and for -CS-NR31 R32 R31 is hydrogen, C1 -7-alkyl, C1-4-alkoxy, C3-7-cycloalkyl , C 1-4 alkylsulfonyl, arylsulfonyl, aryl-C 1-4 alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 alkyl, or C 3-7 cycloalkyl, or wherein R 31 and R 32 together and including the nitrogen atom which are attached form a cyclic residue, substituted with R33, selected from the group consisting of pyrrolidino, piperazino, aziridino or azetidino wherein in the case of pyrrolidino, the substituent R33 must be different from hydrogen, and Het is a heteric residue Ocyclic, substituted with R33, selected from the group consisting of dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, and tetrazole wherein R33 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylcarbonyl, C 1-4-alkoxycarbonyl, halogen, hydroxyl wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl , halogen, hydroxyl, and their salts

7. A compound of the formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkynylcarbonyl or the radical -CO-NR21 R 22, wherein R 21 is C 1-4 -alkyl or C 1-4. -4-C 1-4 alkoxy-alkyl and R 22 is hydrogen or C 1-4 alkyl, R 3 is cyano, an oxazolyl radical, the radical -CO-NR 31 R 32, or the radical -CS-NR 31 R 32, wherein R 31 is C1- 4-alkyl, C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen or C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached they form an aziridino, azetidino, hydroxyazetidino, or piperazino radical, wherein aryl is phenyl or phenyl substituted with C1-4-alkoxy, Arom is phenyl, with the proviso that when R2 is C1-4-alkyl, then R3 is cyano, an oxazolyl radical, the -CO-NR31R32 radical, or the radical -CS-NR31R32, wherein for -CO-NR31R32 R31 is C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen or C1-4alkyl and for -CS-NR31R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino radical , azetidino, hydroxyazetidino, or piperazino, and their salts.

8. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino -C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl and R22 is Hydrogen or C 1-4-alkyl R 3 is the radical -C0-NR 31 R 32, wherein R 31 is C 1-4 -alkyl, R 32 is C 1-4 -alkyl, Arom is phenyl, and salts thereof.

9. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is CI-4-alkyl, R3 is cyano, an oxazolyl radical, the radical -CO-NR31 R32, or the radical -CS-NR31R32, wherein for -CO-NR31R32 R31 is C3-7-cycloalkyl, C1-4-alkylsulfonyl, aryl, C1-4-alkoxy, R32 is hydrogen, C1-4-alkyl and for -CS -NR31 R32 R31 is C1-4-alkyl R32 is C1-4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino, azetidino, hydroxyazetidino, or piperazino radical, wherein aryl is phenyl or phenyl substituted with C 1-4 alkoxy, Arom is phenyl, and their salts.

10. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4- alkylcarbonyl, C 2-4 alkynylcarbonyl or the radical -CO-NR 21 R 22, wherein R 21 is hydrogen, C 1-4 -alkyl or C 1-4 -alkoxy-C 1-4 -alkyl and R 22 is hydrogen, C 1-4 -alkyl or C 1-4-C 1-4 alkoxy-alkyl, R 3 is an oxazolyl radical or the radical -CO-NR 31 R 32, wherein R 31 is C 1-4 -alkyl or C 3-7-cycloalkyl R 32 is hydrogen or C 1-4- alkyl, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, Arom is phenyl, with the proviso that when R2 is C1-4-alkyl, then R3 is an oxazolyl radical or the radical -CO-NR31R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, and their salts.

11. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is hydroxy-C3-4-alkynyl, carboxyl, mono- or di-C1-4-alkylamino - C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO-NR21R22, wherein R21 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl and R22 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl, R3 is the radical -CO-NR31R32, wherein R31 is C1-4-alkyl, R32 is C1-4-alkyl, Arom It is phenyl, and its salts.

12. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl, R3 is an oxazolyl radical or the radical -CO-NR31R32, wherein R31 is C3-7-cycloalkyl R32 is hydrogen, or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an aziridino or azetidino radical, Arom is phenyl, and its salts.

13. A compound of formula 1 as claimed in claim 1, wherein R1 is C1-4-alkyl R2 is carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl or the -CO radical -NR21R22, wherein R21 is hydrogen, C1-4-alkyl or C1-4-alkoxy-C1-4alkyl and R22 is hydrogen, C1-4alkyl or C1-4alkyl-C1-4alkoxy-alkyl, R3 is the radical -CO-NR31R32, wherein R31 is C1-4-alkyl and R32 is C1-4-alkyl Arom is phenyl and its salts.

14. A compound of formula 1 as claimed in claim 1, characterized by the formula 1-a wherein R1 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl, C1- 4-akoxycarbonyl, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or hydroxy-C1-4-alkyl, R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3- 7-cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, hydroxy-C 1-4 -alkyl, hydroxy-C 3-4 -alkenyl, hydroxy-C 3-4 -alkynyl, halogen, C 2-4 -alkenyl, C 2- 4-alkynyl, fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 -alkoxy-C1-4-alkoxycarbonylamino, carboxyl, mono- or di-C1-4-alkylamino-C1-4-alkyl, C1-4-alkylcarbonyl, C2-4-alkenylcarbonyl, C2-4-alkynylcarbonyl or the radical -CO -NR21R22, wherein R21 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl and R22 is hydrogen, C1-7-alkyl , hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, oe n where R21 and R22 together and including the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, aziridino or azetidino radical, R3 is C1-4-alkylcarbonyl, hydroxy-Cl-4-alkyl, C1-4 -alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxycarbonyl, fluoro-C1-4-alkoxy-C1-4-alkyl, cyano , the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical -CS-NR31R32, the radical -C = N (OH) -NR1R32 or the group Het wherein R31 is hydrogen, amino, C1-7-alkyl , hydroxyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-4 -alkylsulfonyl, aryisulfonyl, aryl-C 1-4 -alkylsulfonyl or aryl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the atom of nitrogen to which they are attached form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazi no, morpholino, aziridino or azetidino, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole, isoxazole, dihydroisoxazole, pyrazole, and tetrazole, wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl, carboxyl, C1-4-alkoxycarbonyl, car-boxi-C1- 4-alkyl, C 1-4-alkoxycarbonyl-C 1-4 -alkyl, halogen, hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl-C 1-4 -alkoxy, trifluoromethyl, nitro, amirto, mono- or di- -C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C1-4-alkyl, C1-4-alkoxy, C1 -4-alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R35 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, Arom is an aromatic radical substituted with R4, R5, R6 and R7, mono - or bicyclic, selected from the group consisting of phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furanyl (furyl), benzofuranyl (benzofuryl), thiophenyl (thienyl), benzothiophenyl (benzothienyl) ), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl or isoquinolinyl, wherein R 4 is hydrogen, C 1-4 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 2-4 -alkenyloxy, C 1-4- alkylcarbonyl, carboxyl, C 1-4-alkoxycarbonyl, carboxy-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl-C 1-4 -alkyl, halogen, hydroxyl, aryl, aryl-C 1-4 -alkyl, aryloxy, aryl- C1-4-alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R5 is hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R6 is hydrogen, C1-4alkyl or halogen and R7 is hydrogen, C1-4alkyl or halogen or, wherein aryl is phenyl or substituted phenyl having one, two or three substituents identical or different from the group consisting of C 1-4 -alkyl, C 1-4 -alkoxy, carboxyl, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl, nitro, trifluoromethoxy, hydroxyl and cyano, with the proviso that , when R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkoxycarbonyl, hydroxy-C1-4-alkyl, halogen, C2-4- alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or cyanomethyl, then R3 is C1-4-alkylcarbonyl, cyano, the radical -CO-NR31R32, the radical -SO2-NR31R32, the radical -CS-NR31R32, the radical -C = N (OH) -NR1 R32 or the group Het where for the radical -CO-NR31R32 R31 is amino, hydroxyl, C1-4-alkoxy, C3-7-cycloalkyl, C1-4-alkylsulfonyl, arisulfonyl , aryl-C 1-4-alkylsulfonyl, aryl and R 32 is hydrogen, C 1-7 -alkyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl or C 3-7 -cycloalkyl, and for radicals -SO2-NR31R32, -CS-NR31R32, and -C = N (OH) -NR1R32 R31 is hydrogen, amino, C1-7-alkyl, hydroxyl, hydroxy-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-4 -alkylsulfonyl, aryisulphonyl, aryl-C 1-4 -alkylsulfonyl or aryl and R32 is hydrogen, C1-7-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl or C3-7-cycloalkyl, or wherein R31 and R32 together and including the nitrogen atom at which are joined form a cyclic residue, substituted with R33, R34 and R35, selected from the group consisting of pyrrolidino, piperidino, piperazino, morpholine, aziridino or azetidino where in the case of pyrrolidino, piperidino, or morpholino, at least one of the substituents R33, R34, or R35 must be different from hydrogen, and Het is a heterocyclic residue, substituted with R33, R34 and R35, selected from the group consisting of oxadiazole, dihydrooxazole, dihydroimidazole, oxazole, imidazole , isoxazole, dihydroisoxazole, pyrazole, and tetrazole wherein R33 is hydrogen, C1-4-alkyl, hydroxy-C1-4-alkyl, C1-4-alkoxy, C2-4-alkenyloxy, C1-4-alkylcarbonyl , carboxyl, C1-4-alkoxycarbonyl, carboxy-C1-4-alkyl, C1-4-alkoxycarbonyl-C1-4-alkyl, halogen, hydroxyl, aryl, aryl-C1-4-alkyl, aryloxy, aryl-C1-4 -alkoxy, trifluoromethyl, nitro, amino, mono- or di-C1-4-alkylamino, C1-4-alkylcarbonylamino, C1-4-alkoxycarbonylamino, C1-4-alkoxy-C1-4-alkoxycarbonylamino or sulfonyl, R34 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, R 35 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxycarbonyl, halogen, trifluoromethyl or hydroxyl, and their salts.

15. A compound of formula 1 as claimed in claim 1, characterized by formula 1-as claimed in claim 14, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl or C1-4-alkylcarbonyl, R3 is the radical -CO-NR31 R32 or the radical -CS-NR31 R32, wherein R31 is C1-4-alkyl or C3-7-cycloalkyl, R32 is hydrogen or C1-4-alkyl , or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an azetidino radical, Arom is phenyl, with the proviso that when R2 is C1-4-alkyl, then R3 is the radical -CO. -NR31 R32 or the radical -CS-NR31 R32, wherein for -CO-NR31 R32 R31 is C3-7-cycloalkyl, R32 is hydrogen, and for -CS-NR31 R32 R31 is C1-4-alkyl R32 is C1- 4-alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an azetidino radical, and salts ther

16. A compound of formula 1 as claimed in claim 1, characterized by formula 1-as claimed in claim 14, wherein R1 is C1-4-alkyl, R2 is C1-4-alkyl R3 is the radical -CO-NR31 R32 or the radical -CS-NR31 R32, wherein for -CO-NR31 R32 R31 is C3-7-cycloalkyl, R32 is hydrogen, and for -CS-NR31 R32 R31 is C1-4 - R32 alkyl is C1-4alkyl or wherein R31 and R32 together and including the nitrogen atom to which they are attached form an azetidino radical, Arom is phenyl and its salts.

17. A compound of formula 1 as claimed in claim 1, characterized by the formula 1a as claimed in claim 14, wherein R1 is C1-4-alkyl, R2 is C1-4-alkylcarbonyl, R3 is the radical -CO-NR31 R32, wherein R31 is C1- 4-alkyl, R32 is C1-4-alkyl, Arom is phenyl, and salts thereof.

18. The cyclopropylamide compound of (9S) -2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyran [2,3-c] -imidazo [1,2-a] pyridin-6-acid carboxylic acid and its salts.

19. The compound (9S) - (2,3-dimethyl-9-phenyl-7H-8,9-dihydro-pyrano [2,3-c] -imidazo [1,2-a] pyridin-6-yl) -azetidin-1 -yl methanone and its salts.

20. A medicament comprising a compound as claimed in claim 1 and / or a pharmacologically acceptable salt thereof together with usual auxiliaries and / or pharmaceutical excipients. twenty-one . The use of a compound as claimed in claim 1 and its pharmacologically acceptable salts for the prevention and treatment of gastrointestinal disorders. SUMMARY The invention provides compounds of the formula 1, wherein R 1 is hydrogen, C 1-4 -alkyl, C 3-7 -cycloalkyl, C 3-7-cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy-C 1-4 -alkyl, C 1-4 4-alkoxycarbonyl, C2-4-alkenyl, C2-4-alkynyl, fluoro-C1-4-alkyl or hydroxy-C1-4-alkyl, R2 is hydrogen, C1-4-alkyl, C3-7-cycloalkyl, C3- 7-cycloalkyl-C 1-4 -alkyl, C 1-4 -alkoxycarbonyl, hydroxy-C 1-4 -alkyl, hydroxy-C 3-4 -alkenyl, hydroxy-C 3-4 -alkynyl, halogen, C 2-4 -alkenyl, C 2- 4-Alkynyl, fluoro-C 1-4 -alkyl, cyanomethyl, hydroxyl, C 1-4 -alkoxy, amino, mono- or di-C 1-4 -alkylamino, C 1-4 -alkylcarbonylamino, C 1-4 -alkoxycarbonylamino, C 1-4 4-alkoxy-C 1-4-alkoxycarbonyl, carboxyl, mono- or di-C 1-4-alkylamino-C 1-4 -alkyl, C 1-4 -alkylcarbonyl, C 2-4 -alkenylcarbonyl, C 2-4 -alkynylcarbonyl or radical -CO-NR21R22, R3 is C1-4-alkylcarbonyl, hydroxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C1-4-alkoxy-C1-4-alkoxy-C1 -4-alkyl, C1-4-alkoxycarbonyl, fluoro-C1-4-alkoxy-C1-4-alkyl, cyano, radical -CO-NR31R32, radical -SO2-NR31R32, r adical -CS-NR31R32, radical -C = N (OH) -NR1R32 or Het group. Arom is an aromatic radical substituted with R 4, R 5, R 6 and R 7 mono- or bicyclic, selected from the group consisting of phenyl, naphthyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, indolyl, benzimidazolyl, furanyl (furyl), benzofuranyl (benzofuryl), thiophenyl (thienyl), benzothiophenyl (benzothienyl), thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, quinolinyl and isoquinolinyl. The compounds inhibit the secretion of gastric acid.